CN101205255A - Anti CD20 tetravalent antibody, preparation method and uses thereof - Google Patents
Anti CD20 tetravalent antibody, preparation method and uses thereof Download PDFInfo
- Publication number
- CN101205255A CN101205255A CNA2007101938601A CN200710193860A CN101205255A CN 101205255 A CN101205255 A CN 101205255A CN A2007101938601 A CNA2007101938601 A CN A2007101938601A CN 200710193860 A CN200710193860 A CN 200710193860A CN 101205255 A CN101205255 A CN 101205255A
- Authority
- CN
- China
- Prior art keywords
- ser
- gly
- antibody
- thr
- val
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 title abstract description 16
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 title abstract description 16
- 239000003814 drug Substances 0.000 claims abstract description 18
- 208000003950 B-cell lymphoma Diseases 0.000 claims abstract description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 27
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 18
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 14
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000012216 screening Methods 0.000 claims description 11
- 229940124292 CD20 monoclonal antibody Drugs 0.000 claims description 9
- 230000004927 fusion Effects 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 5
- 238000000926 separation method Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 238000012215 gene cloning Methods 0.000 claims description 3
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 62
- 230000000694 effects Effects 0.000 description 36
- 102220023256 rs387907547 Human genes 0.000 description 20
- 230000006907 apoptotic process Effects 0.000 description 19
- 238000002474 experimental method Methods 0.000 description 19
- 206010028980 Neoplasm Diseases 0.000 description 14
- 238000011579 SCID mouse model Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 239000002953 phosphate buffered saline Substances 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 229960004641 rituximab Drugs 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 230000001640 apoptogenic effect Effects 0.000 description 7
- 210000003719 b-lymphocyte Anatomy 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 102220369447 c.1352G>A Human genes 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- -1 Polyoxyethylene Polymers 0.000 description 5
- 238000000246 agarose gel electrophoresis Methods 0.000 description 5
- 230000000295 complement effect Effects 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 102220023257 rs387907546 Human genes 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 238000010276 construction Methods 0.000 description 4
- 238000000502 dialysis Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000009036 growth inhibition Effects 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 102220023258 rs387907548 Human genes 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 229960000575 trastuzumab Drugs 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 102220369446 c.1274G>A Human genes 0.000 description 3
- 102220369445 c.668T>C Human genes 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 238000013016 damping Methods 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 238000010353 genetic engineering Methods 0.000 description 3
- 230000009422 growth inhibiting effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002502 liposome Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000699802 Cricetulus griseus Species 0.000 description 2
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 240000002853 Nelumbo nucifera Species 0.000 description 2
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 2
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 229960001330 hydroxycarbamide Drugs 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 229920001983 poloxamer Polymers 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000452 restraining effect Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 102000004121 Annexin A5 Human genes 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000003916 Arrestin Human genes 0.000 description 1
- 108090000328 Arrestin Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229940123014 DNA polymerase inhibitor Drugs 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 229940117937 Dihydrofolate reductase inhibitor Drugs 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- CTKXFMQHOOWWEB-UHFFFAOYSA-N Ethylene oxide/propylene oxide copolymer Chemical compound CCCOC(C)COCCO CTKXFMQHOOWWEB-UHFFFAOYSA-N 0.000 description 1
- 108010040476 FITC-annexin A5 Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- 102100026122 High affinity immunoglobulin gamma Fc receptor I Human genes 0.000 description 1
- 101710182312 High affinity immunoglobulin gamma Fc receptor I Proteins 0.000 description 1
- 101100495232 Homo sapiens MS4A1 gene Proteins 0.000 description 1
- 101001094545 Homo sapiens Retrotransposon-like protein 1 Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101710177649 Low affinity immunoglobulin gamma Fc region receptor III Proteins 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027926 Monoplegia Diseases 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 244000221860 Podophyllum emodi Species 0.000 description 1
- 235000010169 Podophyllum emodi Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 102100035123 Retrotransposon-like protein 1 Human genes 0.000 description 1
- 102000000505 Ribonucleotide Reductases Human genes 0.000 description 1
- 108010041388 Ribonucleotide Reductases Proteins 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical group [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 description 1
- 229930188522 aclacinomycin Natural products 0.000 description 1
- USZYSDMBJDPRIF-SVEJIMAYSA-N aclacinomycin A Chemical compound O([C@H]1[C@@H](O)C[C@@H](O[C@H]1C)O[C@H]1[C@H](C[C@@H](O[C@H]1C)O[C@H]1C[C@]([C@@H](C2=CC=3C(=O)C4=CC=CC(O)=C4C(=O)C=3C(O)=C21)C(=O)OC)(O)CC)N(C)C)[C@H]1CCC(=O)[C@H](C)O1 USZYSDMBJDPRIF-SVEJIMAYSA-N 0.000 description 1
- 229960004176 aclarubicin Drugs 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940110282 alimta Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 229960003437 aminoglutethimide Drugs 0.000 description 1
- ROBVIMPUHSLWNV-UHFFFAOYSA-N aminoglutethimide Chemical compound C=1C=C(N)C=CC=1C1(CC)CCC(=O)NC1=O ROBVIMPUHSLWNV-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000051 antiandrogen Substances 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 229940120638 avastin Drugs 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960000397 bevacizumab Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000003995 blood forming stem cell Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229960000975 daunorubicin Drugs 0.000 description 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 239000003166 dihydrofolate reductase inhibitor Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 201000003444 follicular lymphoma Diseases 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 238000005858 glycosidation reaction Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960003881 letrozole Drugs 0.000 description 1
- HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003519 mature b lymphocyte Anatomy 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- GQPLMRYTRLFLPF-UHFFFAOYSA-N nitrous oxide Inorganic materials [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- HYFHYPWGAURHIV-JFIAXGOJSA-N omacetaxine mepesuccinate Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@@](O)(CCCC(C)(C)O)CC(=O)OC)[C@H]4C2=CC2=C1OCO2 HYFHYPWGAURHIV-JFIAXGOJSA-N 0.000 description 1
- 229960002230 omacetaxine mepesuccinate Drugs 0.000 description 1
- 210000004279 orbit Anatomy 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- NYDXNILOWQXUOF-GXKRWWSZSA-L pemetrexed disodium Chemical compound [Na+].[Na+].C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 NYDXNILOWQXUOF-GXKRWWSZSA-L 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 150000003058 platinum compounds Chemical class 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002212 purine nucleoside Substances 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940061969 rheumatrex Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- 238000002626 targeted therapy Methods 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical class CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 229940033942 zoladex Drugs 0.000 description 1
- 229960000641 zorubicin Drugs 0.000 description 1
- FBTUMDXHSRTGRV-ALTNURHMSA-N zorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\NC(=O)C=1C=CC=CC=1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 FBTUMDXHSRTGRV-ALTNURHMSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an anti- CD20 tetravalent antibody and a preparation method as well as application thereof, in particular the invention disclsoes an anti- CD20 tetravalent antibody C2B8(ScFvHL)4-Fc and 2F2(ScFvHL)4-Fc, and the preparation method as well as the use thereof in the preparation of drugs for inhibiting B-cell lymphoma.
Description
Technical field
The present invention relates to the antibody field, more specifically, the invention discloses a kind of anti-tetravalent antibody, its preparation method and its purposes at the anti-B cell lymphoma pharmaceutical methods of preparation.
Background technology
Malignant tumour is the disease of world today's serious harm human health, is in second in death due to the various diseases.Non-Hodgkin lymphoma (Non Hodgkin ' s lymphoma NHL) is clinical modal lymphsystem malignant tumour, and what wherein the B cell was originated accounts for 85%, good sending out in person between twenty and fifty, and sickness rate and case fatality rate are ascendant trend year by year.According to state of an illness characteristics, NHL can be divided into basic, normal, high three degree.The wherein low and part moderate NHL course of disease is made slow progress, and is referred to as inertia NHL.They are to chemotherapy sensitivity first, but are easy to recurrence or resistance, and when chemotherapy or radiotherapy once more, curative effect obviously reduces, thereby are considered to the malignant tumour that is difficult to cure.In recent years, the clinical experimental study of monoclonal antibody and targeted therapy NHL thereof has been obtained major progress, wherein be widely used and fruitful be the monoclonal antibody preparation of anti-CD20.CD20 antigen is a kind of B cell differentiation antigen, only is positioned at pre B cell and mature B cell, and it is expressed in the B cell lymphoma more than 95%, and surface density is very high, and does not express in hemopoietic stem cell, plasma cell and other healthy tissuess.What is more important, the CD20 molecule is with after monoclonal antibody combines, and do not have remarkable internalization and comes off, so become desirable target spot [the Sacchi S of treatment B cell lymphoma, Federico M, Dastoli G, Fiorani C, Vinci G, Clo V, Casolari B.Treatment of B-cell non-Hodgkin ' slymphoma with anti CD 20 monoclonal antibody Rituximab.Crit Rev OncolHematol, 2001,37 (1): 13-25].
Adopt anti-CD20 antibodies treatment non-Hodgkin lymphoma to obtain curative effect preferably at present.Rituxan (Rituximab, C2B8) with CD20 the monoclonal antibody of target spot for U.S. Gene science company development, it is a kind of people mouse mosaic gene engineered antibody, the variable region gene of mouse monoclonal antibody and constant region gene [the Reff ME of people's antibody have been comprised, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, Newman RA, Hanna N, Anderson DR.Depletion of B cells in vivoby a chimeric mouse human monoclonal antibody to CD20.Blood.1994,83 (2): 435-45.].Rituxan has obtained the approval listing of FDA in November, 1997, clinical treatment [the Leget GA that is used for recurrent or intractable minuent or folliculus non-Hodgkin lymphoma, Czuczman MS.Use of rituximab, the new FDA-approved antibody.Curr Opin Oncol.1998; 10:548-551].Although C2B8 antibody has demonstrated curative effect preferably in clinical treatment, treatment does not produce reaction to C2B8 to still have 52% patient.Therefore, seek more to be effective to treat the lymphadenomatous CD20 antibody drug of B and seem particularly urgent.
The possible mechanism of action of anti-CD-20 monoclonal antibody has been set forth in existing many relevant researchs, the cytolysis (CDC effect) that mainly comprises complement-mediated, the cytotoxicity (ADCC) of antibody-dependant cell mediation and to the apoptosis-induced effect (Apoptosis) and the growth-inhibiting effect of tumour cell.And mainly by which kind of mechanism performance antitumor action wherein still exist at issue for anti-CD20 antibodies.; become at present and more and more be clear that; these mechanism are not mutually isolatedly but [the EisenbeisCF that has an effect synergistically mutually; Caligiuri MA, Byrd JC.Rituximab:converging mechanisms of actionin non-Hodgkin ' s lymphoma? Clin Cancer Res.2003; 9:5810-5812.].Therefore we infer, perhaps can produce reaction to the anti-CD20 antibodies of other type and structure, performance different biological function for the insensitive patient of C2B8 Antybody therapy.Anti-CD20 antibodies can be divided into amphitypy according to the difference of its extracorporeal biology function: I type CD20 antibody comprises C2B8 and other most of CD20 antibody, mainly plays a role by the CDC function and apoptotic effect is very weak; And II type CD20 antibody comprises B1 and 11B8, mainly plays a role by apoptosis and the CDC function is very weak.Be used for the clinical treatment except I type antibody C2B8 is granted, II type antibody B1 with
131The traget antibody medicine Tositumomab of I coupling preparation has also got the Green Light and has been used for the treatment of non-Hodgkin lymphomas.What is more important, preclinical test have shown that the naked antibody of 11B8 is same
131Same effectively [the Buchsbaum DJ of the 11B8 antibody of I mark, Wahl RL, Normolle DP, Kaminski MS.Therapy with unlabeled and 131I-labeled pan-B-cellmonoclonal ant ibodies in nude mice bearing Raji Burkitt ' s lymphomaxenografts.Cancer Res.1992; 52:6476-6481].Therefore, because this amphitypy antibody has visibly different biologic activity, will produce reaction to the treatment of II type probably for the insensitive patient of I type Antybody therapy, and vice versa.Thus, we expect that if the existing very strong CDC effect of a kind of antibody possesses very strong apoptosis-induced ability again, it perhaps can more efficientlyly kill and wound CD20
+Tumour cell.
Have obvious enhanced through two anti-CD20 antibody after crosslinked and lure CD20
+Apoptotic effect [Shan D, Ledbetter JA, Press OW.Apoptosis of malignant human B cells by ligation of CD20with monoclonal antibodies.Blood.1998; 91:1644-1652] then infeasible because this method is used for interior therapeutic, thereby people continue to be devoted to prepare the novel and effective antibody molecule.Studies show that, become the antibody of dimeric forms, its apoptotic effect and growth-inhibiting effect all can obviously strengthen [Ghetie MA, Bright H, Vitetta ES.Homodimers but not monomers of Rituxan (chimericanti-CD20) induce apoptosis in human B-lymphoma cells and synergize witha chemotherapeutic agent and an immunotoxin.Blood.2001; 97:1392-1398.].But, produce dimeric mode by chemical crosslink technique and have a lot of defectives, mainly be the molecular weight big (300kDa) and short [the Wolff EA of transformation period of homodimeric antibody, Schreiber GJ, Cosand WL, Raff HV.Monoclonal antibody homodimers:enhanced antitumor activity in nude mice.Cancer Res.1993; 53:2560-2565.Ghetie MA, Podar EM, Ilgen A, Gordon BE, Uhr JW, Vitetta ES.Homodimerization of tumor-reactive monoclonalantibodies markedly increases their ability to induce growth arrest orapoptosis of tumor cells.Proc Natl Acad Sci USA.1997; 94:7509-7514.].
Summary of the invention
In order to address the above problem, applicant of the present invention has carried out a large amount of experiments, adopt genetic engineering technique to make up the tetravalence genetic engineering antibody of two kinds of I type antibody C2B8 and 2F2,2F2 is a kind of total man source anti-CD-20 monoclonal antibody, and its CDC effect is better than C2B8 antibody.Tetravalence anti-CD20 antibodies disclosed by the invention and former parental antibody can combine with the Raji cell-specific, and its relative affinity is similar, but tetravalence anti-CD20 antibodies disclosed by the invention has stronger apoptosis-induced effect and growth inhibition function, and has the advantage of the survival rate that can significantly improve tumor-bearing mice.
Experimental result shows, though tetravalent antibody disclosed by the invention has four antigen binding sites, the molecular weight of the tetravalent antibody that makes up is only than the big 25KDa of parent's two valency antibody, and it is longer than parent's bivalent antibody mouse intravital plasma half-life slightly, shows that the structure height of this tetravalent antibody is stable; Applicant of the present invention so by internal and external test relatively the anti-tumor activity of tetravalent antibody and former parent's bivalent antibody [press Teeling JL, French RR, Cragg MS, et al.Characterization of new human CD20 monoclonalantibodies with potent cytolytic activity against non-Hodgkin lymphomas.Blood.2004; 104:1793-1800 carries out], result of study shows, the tetravalent antibody 2F2 (ScFvHL) of 2F2
4-Fc not only has identical CDC and the ADCC activity with its parent two valency antibody 2F2, and more former bivalent antibody all has obvious enhancing on short apoptosis of tumor cells and growth inhibition function, even is better than the tetravalent antibody C2B8 (ScFvHL) of C2B8
4-Fc.The immunotherapy experiment further confirms tetravalent antibody 2F2 (ScFvHL) in the body
4-Fc obviously is better than other three kinds of antibody on the lifetime that prolongs lotus knurl SCID mouse, can become the lymphadenomatous treatment of B provides the novel antibody medicine.
Utilize genetic engineering technique to make up the tetravalence anti-CD20 antibodies, the invention discloses:
1, a kind of anti-CD 20 tetravalent antibody;
2, above-mentioned 1 described anti-CD 20 tetravalent antibody is C2B8 (ScFvHL)
4-Fc;
3, above-mentioned 2 anti-CD 20 tetravalent antibody, its aminoacid sequence are SEQ ID NO:18;
4, the nucleotide sequence of the above-mentioned 3 described antibody of encoding is SEQ ID NO:17;
5, above-mentioned 1 described anti-CD 20 tetravalent antibody is 2F2 (ScFvHL)
4-Fc;
6, above-mentioned 5 described anti-CD 20 tetravalent antibodies, its aminoacid sequence are SEQ ID NO:20;
7, the nucleotide sequence of the above-mentioned 6 described antibody of encoding is SEQ ID NO:19
8, prepare the method for above-mentioned anti-CD 20 tetravalent antibody, comprising:
A. the single-chain antibody ScFv and the clone that make up CD20 monoclonal antibody c2B8 or 2F2 obtain people's IgG antibody 1Fc gene;
B. link to each other with people's antibody Fc section gene again after 2 identical single-chain antibody genes being connected in series and obtain fusion gene;
C. with above-mentioned fusion gene cloning to carrier for expression of eukaryon pcDNA3.1 (+), be built into carrier for expression of eukaryon pcDNA3.1 (C2B8 (ScFvHL)
2Fc) or pcDNA3.1 (2F2 (ScFvHL)
2Fc);
D. expression vector pcDNA3.1 (C2B8 (ScFvHL)
2Fc) or pcDNA3.1 (2F2 (ScFvHL)
2Fc) transfection CHO cell, subclone is carried out in screening, and with the high-expression clone enlarged culturing that screening obtains, separation and purification is promptly.
9. a preparation contains above-mentioned 1,2,3,5,6 arbitrary described antibody and pharmaceutically useful carriers.
10. above-mentioned 1,2,3,5,6,9 arbitrary described antibody or the preparation purposes in the medicine of the anti-B cell lymphoma of preparation.
11. above-mentioned 10 purposes, wherein B cell lymphoma is a non-Hodgkin lymphoma.
12. above-mentioned 11 purposes, wherein non-Hodgkin lymphoma is low and part moderate non-Hodgkin lymphoma.
13. above-mentioned 10 purposes, wherein B cell lymphoma is a chronic lymphatic leukemia.
More specifically, applicant of the present invention made up single-chain antibody ScFvHL and the ScFvHL of CD20 monoclonal antibody C2B8 and 2F2 at first respectively, and the clone has obtained people's IgG antibody 1, the weight chain constant area gene of κ by a large amount of experiments.Adopt molecule clone technology respectively single-chain antibody gene to be linked to each other with people's antibody Fc section gene on this basis, further with above-mentioned fusion gene cloning to carrier for expression of eukaryon pcDNA3.1 (+), be built into carrier for expression of eukaryon pcDNA3.1 (C2B8 (ScFvHL) respectively
2Fc) and pcDNA3.1 (2F2 (ScFvHL)
2Fc).With expression vector pcDNA3.1 (C2B8 (ScFvHL)
2Fc) and pcDNA3.1 (2F2 (ScFvHL)
2Fc) use liposome method cotransfection Chinese hamster ovary celI respectively, with the G418 screening positive cell clone of 500 μ g/ml.With the high-expression clone serum free medium enlarged culturing that screening obtains, use Protein A affinity column separation and purification anti-CD 20 tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc.
For the present invention, any suitable carrier for expression of eukaryon can use, and these carriers can be pCDNA3.1 (+), pDR1 (Fig. 1), one of pDHFF.
Applicant of the present invention has carried out biological experiment in external, the body to above-mentioned tetravalence anti-CD20 antibodies, and the extracorporeal biology experimental result shows C2B8,2F2, anti-CD 20 tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc can both combine with the Raji cell-specific well, and their relative affinity is similar.But tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4The dissociation rate of-Fc is starkly lower than their parental antibody C2B8 and 2F2 separately respectively; Though have four antigen binding sites, the molecular weight of tetravalent antibody is only than the big 25KDa of parent's two valency antibody; Tetravalent antibody is longer than parent's bivalent antibody mouse intravital plasma half-life slightly, shows that the structure height of this tetravalent antibody is stable; Tetravalent antibody not only has CDC identical with parental antibody and ADCC activity, and more former bivalent antibody all has obvious enhancing on short apoptosis of tumor cells and growth inhibition function, wherein, and tetravalent antibody 2F2 (ScFvHL)
4The effect of-Fc is the strongest, and it has induced the apoptosis of about 30% left and right sides Daudi cell and 23% left and right sides Raji cell when 2 μ g/ml and 10 μ g/ml, and tetravalent antibody C2B8 (ScFvHL)
4The effect of-Fc is taken second place, and it makes Daudi cell about 19% and about 16% Raji cell that apoptosis take place.Equally, 2F2 (ScFvHL)
4-Fc has the ability of the strongest inhibition tumor cell proliferation, and its inhibiting rate when the above concentration of 2 μ g/ml is respectively about 95% (Daudi cell) and 88% (Raji cell), and its effect is better than C2B8 (ScFvHL)
4-Fc antibody, the inhibiting rate of the latter when the above concentration of 2 μ g/ml is respectively about 82% (Daudi cell) and 76% (Raji cell).The immunotherapy experimental result further confirms tetravalent antibody 2F2 (ScFvHL) in the body
4-Fc obviously is better than other three kinds of antibody (C2B8,2F2 and C2B8 (ScFvHL) on the lifetime that prolongs lotus knurl SCID mouse
4-Fc).
Above experimental result illustrates this two kinds of anti-CD 20 tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4The antitumor curative effect of-Fc all obviously is better than their parental antibody c2B8 and 2F2 separately.And 2F2 (ScFvHL)
4The antitumor curative effect of-Fc is best.
The present invention discloses above-mentioned anti-CD 20 tetravalent antibody, thereby can form pharmaceutical preparations composition together with acceptable auxiliary material pharmaceutically and more play consistently curative effect, preparation can be pharmacy field suspendible commonly used, liquid drugs injection, preparations such as freeze-drying, preferred liquid drugs injection or freeze-dried preparation, liquid drugs injection or freeze-dried preparation for above-mentioned anti-CD 20 tetravalent antibody disclosed by the invention, pharmaceutically the acceptable auxiliary material comprises tensio-active agent, solution stabilizer, one of isotonic regulator and damping fluid or its combination, wherein tensio-active agent comprises nonionic surface active agent such as Polyoxyethylene Sorbitol Fatty Acid Esters (polysorbas20 or 80); Poloxamer (as poloxamer 188); Triton; Sodium lauryl sulphate (SDS); Sulfuric acid,monododecyl ester, sodium salt; Tetradecyl, inferior oil base or octadecyl sarkosine; Pluronics; MONAQUAT
TMDeng; its add-on should make anti-CD 20 tetravalent antibody granulating trend minimum; solution stabilizer can be carbohydrate; comprise reducing sugar and nonreducing sugar; amino acids comprises msg powder type or Histidine; alcohols comprises trivalent alcohol; senior sugar alcohol; propylene glycol; one of polyoxyethylene glycol or its combination; keep steady state in the time that the add-on of solution stabilizer should make preparation those skilled in the art of last formation think to reach stable; isotonic regulator can be sodium-chlor; one of N.F,USP MANNITOL, damping fluid can be TRIS; histidine buffering liquid; one of phosphate buffered saline buffer.
Above-mentioned preparation is the composition that comprises anti-CD 20 tetravalent antibody, and after to the animals administer that comprises the people, antitumous effect is obvious.Specifically, to preventing and/or treating effectively of tumour, can be used as the drug use that prevents and/or treats tumour.
Anti-CD 20 tetravalent antibody and composition thereof are when comprising people's animals administer among the present invention, dosage is people's age and body weight due to illness, disease characteristic and seriousness, and route of administration and different, can be with reference to zooperal result and all situations, total dosage can not surpass certain limit.Specifically intravenous dosage is 0.1～3000mg/ days.
Anti-CD 20 tetravalent antibody disclosed by the invention and composition thereof can also and other antitumour drug Combined Preparation, be used for tumor treatment, the medicine that these antitumour drugs comprise 1, cytotoxic drug (1) acts on the DNA chemical structure: alkylating agent such as nitrogen mustards, nitrous urine class, methanesulfonate ester class; Platinum compound such as cis-platinum, carboplatin and RP-54780 etc.; Mitomycin (MMC); (2) influence nucleic acid synthetic medicine: dihydrofolate reductase inhibitor such as Rheumatrex (MTX) and Alimta etc.; Thymus nucleoside synthetase inhibitors such as fluorouracil (5FU, FT-207, capecitabine) etc.; Purine nucleoside synthetase inhibitors such as Ismipur (6-MP) and 6-TG etc.; Ribonucleotide reductase inhibitor such as hydroxyurea (HU) etc.; DNA polymerase inhibitor such as cytosine arabinoside (Ara-C) and strong select (Gemz) etc.; (3) act on the medicine of transcribed nucleic acid: selectively acting suppresses DNA dependenc RNA polysaccharase in dna profiling, thereby suppresses RNA synthetic medicine as dactinomycin, daunorubicin, Zorubicin, pidorubicin, aclacinomycin, Plicamycin etc.; (4) mainly act on tubulin synthetic medicine: taxol, taxotere, vincaleucoblastine, vinorelbine, Podophyllum emodi var chinense alkali class, homoharringtonine; (5) other Cytotoxic drugs: the main arrestin matter of Asparaginase synthetic; 2, hormones estrogen antagonist: tamoxifen, droloxifene, Exemestane etc.; Arimedex: aminoglutethimide, Lan Telong, letrozole, Rui Ningde etc.; Androgen antagonist: its ammonia RH-LH agonist/antagonist of fluorine: Zoladex, enatone etc.; 3, biological response modifier: mainly suppress the tumour Interferon, rabbit by body's immunity; Interleukin II; The Zadaxin class; 4, monoclonal antibody: Cetuximab (C225); Trastuzumab (Trastuzumab) Bevacizumab (Avastin); 5, other draw together some machine-processed at present medicines of failing to understand and remaining further to be studied; Cell differentiation inducer such as retinoids; Cell death inducer.Anti-CD 20 tetravalent antibody disclosed by the invention and composition thereof can with one of above-mentioned antitumor drug or its combinatorial association medication.
The B cell lymphoma of indication of the present invention comprises B cell chronic lymphocytic leukemia, B cell lymphoblast lymphoma, and follicular lymphoma, hairy cell leukemia, the Burkitt lymphoma, lymph-plasma cell lymphomas etc. are enumerated here no longer one by one.
The antitumor drug that the present invention is alleged, the medicine that finger has the tumour of preventing and/or treating, can comprise the delay of following tumor growth related symptoms development and/or the reduction of these severity of symptom, it further comprises alleviating of already present tumor growth simultaneous phenomenon and prevents the appearance of other symptoms, still reduces or prevents and shift.
Description of drawings
Fig. 1 .pDR1 expression vector structural representation; HCMV pro represents human cytomegalovirus M ajorImmediate early promoter; BGH pA represents Bovine growth hormone polyadenous glycosidation signal; SV40ori represents the early stage replication orgin of SV40 virus; DHFR represents dihydrofolate reductase gene; PUCorigin is the plasmid replication starting point; AMP is an ampicillin resistance gene;
Fig. 2 .C2B8 (ScFvHL)
2Fc or 2F2 (ScFvHL)
2The gene structure figure of Fc;
Fig. 3. anti-CD 20 tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc structure iron;
Fig. 4. the SDS-PAGE electrophoretogram of tetravalent antibody and former bivalent antibody.Road 1, molecular weight protein Marker; Road 2, C2B8; Road 3,2F2; Road 4, C2B8 (ScFvHL)
4-Fc; Road 5,2F2 (ScFvHL)
4-Fc.
The western blotting immunoassay of Fig. 5 tetravalent antibody and former bivalent antibody.Road 1, molecular weight protein Marker; Road 2, C2B8; Road 3,2F2; Road 4, C2B8 (ScFvHL)
4-Fc; Road 5,2F2 (ScFvHL)
4-Fc.
The activity identification result of Fig. 6 anti-CD 20 tetravalent antibody.The bonding force of Fig. 6-1 antibody and Raji cell; Fig. 6-2, C2B8 (ScFvHL)
4-Fc and former parent's bivalent antibody C2B8 competition combine with the Raji cell; Fig. 6-3,2F2 (ScFvHL)
4-Fc and former parent's bivalent antibody 2F2 competition combine with the Raji cell; Fig. 6-4, anti-CD20 antibodies combines with human complement component Clq's; Fig. 6-5, anti-CD20 antibodies combines with FcR (U937 cell); Fig. 6-6, the detection of anti-CD20 antibodies dissociation yield.
Fig. 7 anti-CD20 antibodies inductive CDC and ADCC exercising result, X-coordinate is an antibody concentration among each figure, the ug/ml of unit.
Fig. 8 anti-CD20 antibodies inductive apoptotic effect result.Fig. 8-1 anti-CD20 antibodies is induced Daudi apoptosis exercising result, and Fig. 8-2 anti-CD20 antibodies is induced Raji apoptosis exercising result.
Fig. 9 anti-CD20 antibodies is to the growth-inhibiting effect of tumour cell.Daudi (Fig. 9-1) and Raji (Fig. 9-2) cell respectively with the anti-CD20 antibodies of different concns in CO
2Incubator is hatched, and trypan blue exclusion method counting cells every day amounts to several five days.Daudi (Fig. 9-3) and Raji (Fig. 9-4) cell respectively with the anti-CD20 antibodies of different concns in CO
2Incubator is hatched, and measures inhibitory rate of cell growth with the MTT staining on 5th.
Figure 10 anti-CD20 antibodies is to therapeutic action in the tumor-bearing mice.PBS (◆); Anti-her2 (◇); C2B8 (●); 2F2 (); C2B8 (ScFvHL) 4-Fc (▲); 2F2 (ScFvHL) 4-Fc (■), wherein X-coordinate is a fate, ordinate zou is survival rate (per-cent).
Embodiment
Following examples, experimental example only are further detailed the present invention, should not be construed as limitation of the present invention.Embodiment does not comprise the detailed description to traditional method, be used for the method that carrier construction and matter are drawn as those, the gene of proteins encoded being inserted into the method for such carrier and plasmid or plasmid being introduced the method for host cell. such method is well-known for the person having ordinary skill in the art, and in many publications, all describe to some extent, comprise Sambrook, J., Fritsch, E.F.and Maniais, T. (1989) Molecular Cloning:A Laboratory Manual, 2
NdEdition, Coldspring Harbor Laboratory Press.
Embodiment 1. anti-CD20 single-chain antibodies gene constructed
With reference to United States Patent (USP) 6,399,061 disclosed anti-humen CD 20 monoclonal antibody data and sequence entrusts Shanghai to give birth to the variable region of heavy chain (V of the synthetic anti-humen CD 20 monoclone antibody C2B8 of the full gene of worker biotechnology company limited
H) and variable region of light chain (V
L) gene.SEQ ID NO:1 and SEQ ID NO:2 have shown the nucleotide sequence and the aminoacid sequence of the variable region of heavy chain of C2B8 monoclonal antibody respectively.SEQ ID NO:3 and SEQ ID NO:4 have shown the nucleotide sequence and the aminoacid sequence of the variable region of light chain of 2B8 monoclonal antibody respectively.Adopt the method for Overlapping PCR that 3 ' of 2B8 variable region of heavy chain-end is passed through (Gly
4Ser)
35 ' of joint and its variable region of light chain-end merges, and constitutes single-chain antibody gene C2B8 (ScFvHL).SEQ ID NO:5 and SEQ ID NO:6 have shown (Gly respectively
4Ser)
3The nucleotide sequence of joint and aminoacid sequence.SEQ ID NO:7 and SEQ ID NO:8 have shown the nucleotide sequence and the aminoacid sequence of C2B8 (ScFvHL) respectively.The PCR product cloning to pGEM-T carrier (Promega company product), is confirmed to have obtained correct clone after the sequence verification.Correct clone's note in this example is made pGEM-T/C2B8 (ScFvHL).
With reference to PCT patent WO 2004/035607A2 disclosed anti-humen CD 20 monoclonal antibody data and sequence, entrust Shanghai to give birth to the variable region of heavy chain (V of the synthetic anti-humen CD 20 monoclone antibody 2F2 of the full gene of worker biotechnology company limited
H) and variable region of light chain (V
L) gene.The construction process of 2F2 single-chain antibody gene 2F2 (ScFvHL) is with the construction process of C2B8 single-chain antibody gene C2B8 (ScFvHL).SEQ ID NO:9 and SEQ ID NO:10 have shown the nucleotide sequence and the aminoacid sequence of 2F2 (ScFvHL) respectively.At last pGEM-T carrier (Promega company product) is arrived in 2F2 (ScFvHL) gene clone that builds, confirm to have obtained correct clone after the sequence verification.Correct clone's note in this example is made pGEM-T/2F2 (ScFvHL).
The clone of embodiment 2. human antibody heavy chain's constant region genes
Separate healthy human lymphocyte with lymphocyte separation medium (ancient cooking vessel state biotech development company product), extract total RNA with Trizol reagent (Invitrogen company product), according to document (Nucleic AcidsResearch, 1982,10:4071-4079) Bao Dao sequence designs primer CH respectively justice: GCT TCCACC AAG GGC CCA TC and primer CH antisense TTT ACC GGG AGA CAG adopt PCR reaction amplification heavy chain of antibody constant region gene.Warm start is adopted in PCR reaction, reaction conditions: 94 ℃ 5 minutes; 94 ℃ 45 seconds, 60 ℃ 45 seconds, 72 ℃ 1 minute 10 seconds, 30 circulations; 72 ℃ 10 minutes.The PCR product reclaims and is cloned in the pGEM-T carrier through the agarose gel electrophoresis purifying, confirms to have obtained correct clone after the sequence verification.SEQ ID NO:11 and SEQ ID NO:12 have shown CH (C respectively
H) nucleotide sequence and aminoacid sequence.Correct clone's note in this example is made pGEM-T/C
H
With pGEM-T/C
HBe template, design primers F c has adopted GAA TTC GCC GCT GCA GAG CCC AAATCT CCC GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA and Fc antisense TCT AGA TTTACC GGG AGA CAG GGA to obtain the Fc gene of people's IgG antibody 1 by PCR reaction amplification, make it 5 ' contain restriction enzyme sites EcoRI, 3 ' end contains restriction enzyme sites XbaI, and changes the Hinge district in the Fc gene into HingeM.SEQ ID NO:13 and SEQ ID NO:14 have shown nucleotide sequence and the aminoacid sequence of Fc respectively.Reclaim the PCR product and be cloned in the pGEM-T carrier through the agarose gel electrophoresis purifying, note is made pGEM-T (Fc), the screening positive clone order-checking.The Fc gene that order-checking is correct downcuts from the pGEMT carrier with EcoRI and the two enzymic digestions of XbaI, is cloned among the pcDNA3.1 (+) (Invitrogen company product), is built into pcDNA3.1 (Fc) carrier.With plasmid pcDNA3.1 (Fc) HindIII and EcoRI double digestion, purifying reclaims the disconnected pcDNA3.1Fc of enzyme section behind agarose gel electrophoresis.
With pGEM-T/C2B8 (ScFvHL) is template, design primer C2B8 (ScFvHL) 1 has adopted AAG CTT ATGGGA TTC AGC AGG ATC TTT CTC and C2B8 (ScFvHL) 1 antisense GCT AGC TCG TTT GATCTC CAG CTT GGT C to obtain anti-CD20 single-chain antibody gene by pcr amplification and makes it 5 ' contain restriction enzyme sites HindIII, and 3 ' end contains restriction enzyme sites NheI.Reclaim the PCR product and be cloned in the pGEM-T carrier through the agarose gel electrophoresis purifying, note is made pGEM-T C2B8 (ScFvHL) 1, the screening positive clone order-checking.The clone that order-checking is correct reclaims the disconnected C2B8 (ScFvHL) 1 of enzyme section with HindIII and the two enzymic digestions of NheI.With pGEM-T/ScFv is template, design primer C2B8 (ScFvHL) 2 has adopted GCT AGCACT GGT AGT CAG GTA CAA CTA CAG CAG CCT GGG GCT GAG CTG and C2B8 (ScFvHL) 2 antisense GAA TTC TCG TTT GAT CTC CAG CTT G to obtain anti-CD20 single-chain antibody gene by pcr amplification and makes it 5 ' contain restriction enzyme sites NheI, and 3 ' end contains restriction enzyme sites EcoRI.Reclaim the PCR product and be cloned in the pGEM-T carrier through the agarose gel electrophoresis purifying, note is made pGEM-TC2B8 (ScFvHL) 2, the screening positive clone order-checking.The clone that order-checking is correct reclaims the disconnected C2B8 (ScFvHL) 2 of enzyme section with NheI and the two enzymic digestions of EcoRI.
The section of three enzymes disconnected C2B8 (ScFvHL) 1, C2B8 (ScFvHL) 2 and the pcDNA3.1Fc of above-mentioned acquisition are connected with T4 dna ligase (Invitrogen company product), be built into carrier for expression of eukaryon pcDNA3.1 (C2B8 (ScFvHL)
2Fc).Accompanying drawing 2 is C2B8 (ScFvHL)
2The gene structure figure of Fc.It is the joint of fifteen amino acid that a length is arranged between two single-chain antibodies, and SEQ ID NO:15 and SEQ ID NO:16 have shown the nucleotide sequence and the aminoacid sequence of joint respectively.SEQ ID NO:17 and SEQ ID NO:18 have shown C2B8 (ScFvHL) respectively
2The nucleotide sequence of Fc and aminoacid sequence.
Adopt and C2B8 (ScFvHL)
2The method that Fc fusion gene building mode is identical makes up the expression vector pcDNA3.1 (2F2 (ScFvHL) of 2F2 tetravalent antibody
2Fc).Accompanying drawing 2 is 2F2 (ScFvHL)
2The gene structure figure of Fc.SEQ ID NO:19 and SEQ ID NO:20 have shown 2F2 (ScFvHL) respectively
2The nucleotide sequence of Fc gene and aminoacid sequence.
In 3.5cm tissue culture ware, inoculate 3.5 * 10
5The Chinese hamster ovary celI in/hole is cultured to when 90-95% merges and carries out transfection: gets 10 μ g pcDNA3.1 (C2B8 (ScFvHL)
2Fc) or pcDNA3.1 (2F2 (ScFvHL)
2Fc) plasmid is dissolved in 500 μ l serum-free DMEM substratum respectively with 20 μ l Lipofectamine2000 reagent [Invitrogen company product] respectively, room temperature left standstill 5 minutes, with above 2 kinds of liquid mixing, incubated at room 20 minutes is so that the formation of DNA-liposome complex, therebetween with the blood serum medium that contains in the DMEM substratum replacement culture dish of 3ml serum-free, then the DNA-liposome complex that forms is joined in the plate CO
2Incubator is cultivated after 4 hours and is added the DMEM perfect medium that 3ml contains 10% serum, places CO
2Continue in the incubator to cultivate.Transfection is carried out after 24 hours cell by 0.8 * 10
5/ ware passes in the 10cm culture dish, adds the G418 screening positive cell clone of 500 μ g/ml.With high-expression clone serum free medium (the JRH Biosciences company product) enlarged culturing that screening obtains, use ProteinA affinity column (GE company product) separation and purification CD20 tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc.Antibody purification is dialysed with PBS, at last with the uv-absorbing standard measure.Accompanying drawing 3 is tetravalent antibody C2B8 (ScFvHL)
4-Fc or 2F2 (ScFvHL)
4The structure iron of-Fc.
Experimental example
The labelling experiment of experimental example 1 antibody
With dialysis labelling method traget antibody: with the carbonate buffer solution of 0.025M pH9.5 antibody (C2B8,2F2, C2B8 (ScFvHL) with preliminary making
4-Fc, 2F2 (ScFvHL)
4The humanized antibody Trastuzumab (Anti-her2) of-Fc or anti-people her2) is diluted to 1% concentration, in the dialysis tubing of packing into.With same damping fluid the solution that FITC is made into 0.1mg/ml is contained in small beaker, dialysis tubing is immersed in the FITC solution, stir 24h 4 ℃ of lucifuges.Take out marking fluid in the dialysis tubing, cross post with Sephadex G-50, remove free fluorescein, it is standby to collect fluorescence antibody.C2B8 and Trastuzumab are available from Luo Shi (China) company limited.2F2 antibody by us according to document [Li BH, Wang H, Dai JX, Ji JJ, Qian WZ, Zhang DP, HouS, Guo YJ.Construct ion and characterization of a humanized anti-humanCD3 monoclonal antibody 12F6 with effective immunoregulation functions.Immunology.2005,116 (4): 487-98] method of the anti-people CD3 humanized antibody hu12F6 of preparation makes up voluntarily and prepares in.
Experimental example 2 SDS-PAGE and Western-blot detect tetravalent antibody
Tetravalent antibody behind the purifying detects its purity and molecular weight size (Fig. 4) with polyacrylamide gel electrophoresis respectively under non-reduced (6%) and reduction (12%) condition, further identify its character and molecular weight (Fig. 5) by Western-blot simultaneously.The Western-blot method is as follows: the method for the glue behind the electrophoresis by electrotransfer is transferred on the pvdf membrane, and the sealing back adds the goat anti-human igg (H+L) of HRP mark, and PBST washes twice, last DAB method colour developing.The result of polyacrylamide gel electrophoresis and Western-blot shows: under reductive condition, C2B8 antibody and 2F2 antibody all are rendered as heavy chain and the light chain of molecular weight about 55KDa of size and 25KDa, and tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc then is reduced to a band, and its molecular weight size is about 93KDa.Under non-reduced condition, all antibody all present a band, and their size is respectively 150KDa (C2B8 antibody), 162KDa (2F2 antibody), 175KDa (C2B8 (ScFvHL)
4-Fc antibody) and 186KDa (2F2 (ScFvHL)
4-Fc).These results show, though our constructed tetravalent antibody has four antigen binding sites, its molecular weight is only than the big 25KDa of original parental antibody.
The determination of activity of experimental example 3 anti-CD 20 tetravalent antibodies
The bonding force experiment of Flow cytometry tetravalent antibody and Raji cell
1 * 10
6The tetravalent antibody of the Raji cell of/ml and different concns FITC mark 4 ℃ hatch 1 hour altogether after, the flow cytometer fluorescence intensity.Show (Fig. 6-1), tetravalent antibody C2B8 (ScFvHL) with the bonding force experimental result of Raji cell
4-Fc and 2F2 (ScFvHL)
4Each self-corresponding C2B8 antibody of-Fc and they has similar binding curve with 2F2 antibody, all is the concentration gradient dependency, shows that they have identical with 2F2 antibody with C2B8 and the antigenic binding ability of CD20.
The fluorescence competition is in conjunction with experiment
The C2B8 or the 2F2 antibody (C2B8-FITC or 2F2-FITC) of sub-saturated concentration FITC mark are mixed back and 1 * 10 with the anti-CD20 antibodies of different concns
6The Raji cell of/ml is hatched (4 ℃, 1 hour), Flow cytometry fluorescence intensity.Experimental result shows that tetravalent antibody has avidity similar to former bivalent antibody and specificity (Fig. 6-2, Fig. 6-3).
The experiment that combines of tetravalent antibody and human complement component Clq
1 * 10
6The Raji cell of/ml and 2 μ g/ml anti-CD20 antibodies were hatched 15 minutes in 37 ℃, PBS washes later and adds (37 ℃ of human serums by 1% volume ratio, 15 minutes), after PBS washes twice, the cotton goat-anti people Clq monoclonal antibody (Serotec company product) that adds the FITC mark was hatched 30 minutes in 4 ℃, used the Flow cytometry fluorescence intensity at last.The experimental result that combines of antibody and complement component C1 q shows (Fig. 6-4), 2F2 in conjunction with the quantity of Clq obviously more than C2B8, and tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc is similar with 2F2 to their parental antibody C2B8 separately in conjunction with the quantity of Clq.
The experiment that combines of tetravalent antibody and FcR (U937 cell)
Human cell line U937 is the clone of great expression FcRI and FcRIII, can realize with combining of U937 cell by the Flow cytometry tetravalent antibody with combining of FcR so detect tetravalent antibody.Method is as follows: the U937 cell is induced the expression (CO of FcR in advance with 500U/ml INF-γ
2Incubator effect 24h), PBS washes later the Anti-her2-FITC of sub-saturated concentration added altogether with the anti-CD20 antibodies of different concns hatches (4 ℃, 1 hour), measure tetravalent antibody combines FcR with anti-her2 antibody competition ability by the Flow cytometry fluorescence intensity.The result of Fig. 6-5 shows, 2F2, C2B8, C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc has the identical ability in conjunction with FcR, and the tetravalent antibody of pointing out us to make up may have the ADCC effect.
The test experience of tetravalent antibody dissociation yield
The anti-CD20 antibodies (10 μ g/ml) of Raji cell and saturation concentration FITC mark was hatched 1 hour in 37 ℃, wash twice back perfect medium re-suspended cell of cell, detect with flow cytometry in different time points then, calculate and still to be incorporated into the percentage that antibody on the cell accounts for initial binding antibody.From the dissociation yield result of experiment that Fig. 6-6 shows, we can see, the speed of C2B8 antibody dissociation is obviously faster than 2F2 antibody, dissociating of tetravalent antibody then is considerably slower than its corresponding bivalent antibody, show that tetravalent antibody has the antigen binding site more than two, therefore can on cell, stop the longer time.
Experimental example 4 anti-CD20 antibodies inductive CDC and ADCC effect experiment: the detection of cell killing experiment
(ADCC) experiment that kills and wounds of the cell killing of complement-mediated (CDC) experiment and antibody-dependant cell mediation detects by LDH on-radiation test kit (Promega company product).Method is as follows: cell and antibody in no phenol red DMEM substratum at CO
2After incubator is hatched 1 hour, add human serum (being used to measure CDC) or press the effect target than the human peripheral blood single nucleus cell (being used to measure ADCC) that adds fresh separated at 50: 1, in CO by 10% volume ratio
2After incubator is hatched 4 hours, the colour developing of LDH on-radiation test kit.0.2%Triton X-100 is used as 100% contrast that kills and wounds.CDC result is as shown in Figure 7: 2F2 antibody and 2F2 (ScFvHL)
4The ability that-Fc antibody kills and wounds the Daudi cell obviously is better than C2B8 antibody and its tetravalent antibody C2B8 (ScFvHL)
4-Fc, same result also is confirmed in the Raji cell.Fig. 7 has also shown the ADCC effect of different antibodies mediation under the different concns, and by the result as can be seen, the ADCC effect of four kinds of antibody is basic identical.
The apoptosis-induced experiment of experimental example 5 anti-CD20 antibodies
The anti-CD20 antibodies of cell and different concns is in CO
2After the incubator effect 18 hours, with Annexin V (Annexin V-FITC) dyeing of FITC mark, the ratio of Flow cytometry viable apoptotic cell.Experimental result (Fig. 8) shows, in Daudi (Fig. 8-1) and two groups of cells of Raji (Fig. 8-2), under the condition of different antibodies concentration, bivalent antibody C2B8 and 2F2 induce the apoptotic effect all very weak (＜10%) of generation, but and the obvious enhanced apoptotic effect of tetravalent antibody induction ratio bivalent antibody.Seemingly interesting, though C2B8 antibody is similar with the ability of 2F2 antibody induction apoptosis, and their pairing tetravalent antibodies have visibly different apoptosis-induced ability.Tetravalent antibody 2F2 (ScFvHL)
4The effect of-Fc is the strongest, and it has induced the apoptosis of about 30% left and right sides Daudi cell and 23% left and right sides Raji cell when 2 μ g/ml and 10 μ g/ml, and tetravalent antibody C2B8 (ScFvHL)
4A little less than the effect of-Fc, in the employed concentration range of experiment, it can make Daudi cell about 19% and about 16% Raji cell generation apoptosis at most.
Experimental example 6 anti-CD20 antibodies are to the cell growth inhibition test of tumour cell
2 * 10
5The Raji of/ml and Daudi cell respectively with the anti-CD20 antibodies of different concns in CO
2Incubator is hatched, and trypan blue exclusion method counting cells every day amounts to several five days, and the 5th again with calculating growth inhibition ratio behind the MTT staining dyeing reading.Fig. 9-1 and Fig. 9-2 shows, through tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4Daudi and Raji cell that-Fc handles, the speed of its cell proliferation is considerably slower than the cell through bivalent antibody C2B8 and 2F2 processing, and the multiplication rate of these four kinds of cells that anti-CD20 antibodies is handled is considerably slower than the cell of unprocessed and anti-her2 antibody treatment, and this explanation bivalent antibody and tetravalent antibody all have inhibition CD20
+The effect of cell growth, and the effect of tetravalent antibody obviously is better than the effect (P＜0.05) of bivalent antibody; What Fig. 9-3 and Fig. 9-4 showed is the inhibiting rate that mtt assay dyes and calculated behind the cell quantity in the 5th day, and C2B8 antibody has identical restraining effect with 2F2 antibody under same concentrations, and the restraining effect of tetravalent antibody then has obvious enhancing; Comparatively speaking, 2F2 (ScFvHL)
4The inhibiting rate of-Fc antibody when the above concentration of 2 μ g/ml is respectively about 95% (Daudi cell) and 88% (Raji cell), and its effect is better than C2B8 (ScFvHL)
4-Fc antibody, the latter's the highest inhibiting rate in the employed concentration range of experiment is respectively 82% (Daudi cell) and 76% (Raji cell).
The experiment of experimental example 7 pharmacokineticss
8 ages in week, female ICR mouse was divided four groups, each only organizes the different anti-CD20 antibodies 50 μ g/ of difference tail vein injection, blood is got in eye socket anti-freezing every other day, every mouse is only got blood once, centrifugal collection blood plasma freezes in-80 ℃ of cryogenic refrigerators, gets continuously 40 days, according to document [Rebello P, Hale G Pharmacokinetics ofCAMPATH-1H:assay development and validation.J Immunol Methods.2002; 260:285-302] in similar methods measure the concentration of anti-CD20 antibodies in the blood plasma with flow cytometry: 1 * 10
6The Raji cell of/ml and plasma sample 4 ℃ hatch 1 hour altogether after, add the anti-people's antibody of FITC labelled goat, detect with flow cytometer then.Pharmacokinetic parameter is as shown in table 1, and C2B8 antibody has identical plasma half-life with 2F2 antibody in ICR mouse body, and tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4Then be longer than bivalent antibody the plasma half-life of-Fc slightly, the result of other pharmacokinetic parameter with plasma half-life the result consistent.
The pharmacokinetic parameter of table 1. antibody.
| Antibody type | t 1/2(hour) | AUC | MRT (hour) |
| ?C2B8 ?C2B8(ScFvHL) 4-Fc ?2F2 ?2F2(ScFvHL) 4-Fc | 109.3 119.5 101.8 112.3 | 6269.1 6438.4 5618.3 6451.6 | 156.7 169.1 145.6 161.1 |
The immunotherapy experiment of experimental example 8 anti-CD20 antibodies
The SCID mouse is divided 28 groups, and 10 every group, each group is tail vein injection 3.5 * 10 respectively
6Raji or Daudi cell were injected the antibody of different sorts and dosage on the 5th day again, were respectively 5 μ g/ only, 15 μ g/ only and 50 μ g/ only, observe the state of mouse every day, when hind leg paralysis occurring, put to death animal.And, adopt the log-rank method of inspection to carry out statistical analysis relatively according to Kaplan-Meier rule drafting survival curve.As shown in figure 10: after antibody was with 5 μ g/ dosage injection only, the result of treatment of C2B8 antibody in the Daudi-SCID mouse compared with PBS did not have tangible significant difference (P=0.0611); And use 2F2 antibody, tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4The Daudi-SCID mouse survival time that-Fc handles but have significant prolongation (with regard to every group respectively with PBS or C2B8 antibody treatment group comparatively speaking, P＜0.0001), C2B8 (ScFvHL) wherein
4The ability similar (P=0.0794) of-Fc antibody and 2F2 antibody prolongation Daudi-SCID mouse survival rate.It should be noted that tetravalent antibody 2F2 (ScFvHL)
4The result of treatment of-Fc is than C2B8 antibody, 2F2 antibody and C2B8 (ScFvHL)
4The result of treatment of-Fc antibody is all good (with regard to 2F2 (ScFvHL)
4-Fc treatment group respectively comparatively speaking with other three groups of anti-CD20 antibodies treatment group, P＜0.0001).Same, in the experimental group of the anti-CD20 antibodies treatment Raji-SCID mouse model that uses same dosage, the result of treatment that each Antybody therapy group is obtained is consistent with the result of Daudi-SCID mouse model.
In 15 μ g/ injected dose group only, C2B8 antibody, 2F2 antibody, tetravalent antibody C2B8 (ScFvHL)
4-Fc and 2F2 (ScFvHL)
4-Fc has all shown tangible result of treatment (P＜0.001 is contrast with PBS).Comparatively speaking, still exist notable difference (P＜0.0001) between C2B8 Antybody therapy group and other three kinds of Antybody therapy groups.What deserves to be mentioned is, in the Raji-SCID mouse model, C2B8 (ScFvHL)
4The result of treatment of-Fc antibody is better than 2F2 antibody (P＜0.001), and in the Daudi-SCID mouse model, C2B8 (ScFvHL)
4The result of treatment of-Fc antibody and 2F2 antibody is no significant difference (P=0.2297) then.Especially it should be noted that tetravalent antibody 2F2 (ScFvHL)
4The result of treatment of-Fc is best (P＜0.0001 is compared with other each treatment group respectively) in all antibody, and the mouse death rate in the time of the 100th day only is 20%.
The conclusion of Figure 10 also shows, the survival time that can prolong tumor-bearing mice by the dosage that improves anti-CD20 antibodies.When the dosage of treatment antibody reaches 50 μ g/, compare C2B8 (ScFvHL) with C2B8 antibody
4The antitumous effect of-Fc antibody and 2F2 antibody increases significantly (P＜0.001), but at 2F2 antibody and C2B8 (ScFvHL)
4No difference of science of statistics (P=0.6310 in the Daudi-SCID mouse, P=0.4379 in the Raji-SCID mouse) then between the-Fc Antybody therapy group.And statistics also shows, low dosage 2F2 (ScFvHL)
4The effect of-Fc Antybody therapy tumor-bearing mice and high dosage C2B8 (ScFvHL)
4The effect of-Fc antibody or 2F2 Antybody therapy is close; Even and C2B8 antibody is in the high-dose therapy group, its result of treatment low dosage 2F2 (ScFvHL) that also is far from
4The result of treatment of-Fc antibody is strong.These results show, tetravalent antibody 2F2 (ScFvHL)
4-Fc has than other three kinds of antibody (C2B8,2F2 and C2B8 (ScFvHL)
4-Fc) stronger antitumor action (2F2 (ScFvHL)
4-Fc treatment group compares P＜0.0001 with other three groups of Antybody therapy groups respectively), it is Daudi-SCID and the Raji-SCID tumor-bearing mice long-term surviving (＞100 days) in all treatment groups when high dosage (50 μ g/ are only).
Statistical analysis technique
Adopt the t check except that the immunotherapy test, P＜0.05 is for there being statistical significance.
SEQUENCE?LISTING
＜110〉Shanghai CP Guojian Pharmaceutical Co.,Ltd
Shanghai Guojian Biotechnology Institute
＜120〉anti-CD 20 tetravalent antibody, its preparation method and application
<130>Homodimers?but?not?monomers?of?Rituxan(chimeric?anti-CD20)induce?apoptosis?in?human?B-lymphoma?cells?and?synergize?with?achemotherapeutic?agent?and?an?immunotoxin.Blood.2001?Mar1；97(5)：1392-8
<150>CN200610147283.8
<151>2006-12-14
<160>20
<170>PatentIn?version3.4
<210>1
<211>420
<212>DNA
＜213〉artificial sequence
<400>1
atgggattca?gcaggatctt?tctcttcctc?ctgtcagtaa?ctacaggtgt?ccactcccag 60
gtacaactac?agcagcctgg?ggctgagctg?gtgaagcctg?gggcctcagt?gaagatgtcc 120
tgcaaggctt?ctggctacac?atttaccagt?tacaatatgc?actgggtaaa?gcagacacct 180
ggtcggggcc?tggaatggat?tggagctatt?tatccaggaa?atggtgatac?ttcctacaat 240
cagaagttca?agggcaaggc?cacactgact?gcagacaaat?cctccagcac?agcctacatg 300
cagctcagca?gcctgacatc?tgaagactct?gcggtctatt?actgtgcaag?atcgacttac 360
tacggcggtg?actggtactt?caatgtctgg?ggcgcaggga?ccacggtcac?cgtctctgca?420
<210>2
<211>140
<212>PRT
＜213〉artificial sequence
<400>2
Met?Gly?Phe?Ser?Arg?Ile?Phe?Leu?Phe?Leu?Leu?Ser?Val?Thr?Thr?Gly
1 5 10 15
Val?His?Ser?Gln?Val?Gln?Leu?Gln?Gln?Pro?Gly?Ala?Glu?Leu?Val?Lys
20 25 30
Pro?Gly?Ala?Ser?Val?Lys?Met?Ser?Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe
35 40 45
Thr?Ser?Tyr?Asn?Met?His?Trp?Val?Lys?Gln?Thr?Pro?Gly?Arg?Gly?Leu
50 55 60
Glu?Trp?Ile?Gly?Ala?Ile?Tyr?Pro?Gly?Asn?Gly?Asp?Thr?Ser?Tyr?Asn
65 70 75 80
Gln?Lys?Phe?Lys?Gly?Lys?Ala?Thr?Leu?Thr?Aia?Asp?Lys?Ser?Ser?Ser
85 90 95
Thr?Ala?Tyr?Met?Gln?Leu?Ser?Ser?Leu?Thr?Ser?Glu?Asp?Ser?Ala?Val
100 105 110
Tyr?Tyr?Cys?Ala?Arg?Ser?Thr?Tyr?Tyr?Gly?Gly?Asp?Trp?Tyr?Phe?Asn
115 120 125
Val?Trp?Gly?Ala?Gly?Thr?Thr?Val?Thr?Val?Ser?Ala
130 135 140
<210>3
<211>387
<212>DNA
＜213〉artificial sequence
<400>3
atggattttc?aagtgcagat?tttcagcttc?ctgctaatca?gtgcttcagt?cataatgtcc 60
agaggacaaa?ttgttctctc?ccagtctcca?gcaatcctgt?ctgcatctcc?aggggagaag 120
gtcacaatga?cttgcagggc?cagctcaagt?gtaagttaca?tccactggtt?ccagcagaag 180
ccaggatcct?cccccaaacc?ctggatttat?gccacatcca?acctggcttc?tggagtccct 240
gttcgcttca?gtggcagtgg?gtctgggacc?tcttactctc?tcacaatcag?tagagtggag 300
gctgaagatg?ctgccactta?ttactgccag?cagtggacta?gtaacccacc?cacgttcggt 360
ggtgggacca?agctggagat?caaacga 387
<210>4
<211>129
<212>PRT
＜213〉artificial sequence
<400>4
Met?Asp?Phe?Gln?Val?Gln?Ile?Phe?Ser?Phe?Leu?Leu?Ile?Ser?Ala?Ser
1 5 10 15
Val?Ile?Met?Ser?Arg?Gly?Gln?Ile?Val?Leu?Ser?Gln?Ser?Pro?Ala?Ile
20 25 30
Leu?Ser?Ala?Ser?Pro?Gly?Glu?Lys?Val?Thr?Met?Thr?Cys?Arg?Ala?Ser
35 40 45
Ser?Ser?Val?Ser?Tyr?Ile?His?Trp?Phe?Gln?Gln?Lys?Pro?Gly?Ser?Ser
50 55 60
Pro?Lys?Pro?Trp?Ile?Tyr?Ala?Thr?Ser?Asn?Leu?Ala?Ser?Gly?Val?Pro
65 70 75 80
Val?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Ser?Tyr?Ser?Leu?Thr?Ile
85 90 95
Ser?Arg?Val?Glu?Ala?Glu?Asp?Ala?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Trp
100 105 110
Thr?Ser?Asn?Pro?Pro?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Glu?Ile?Lys
115 120 125
Arg
<210>5
<211>45
<212>DNA
＜213〉artificial sequence
<400>5
ggcggtggag?gctctggtgg?aggcggttca?ggaggcggtg?gatct 45
<210>6
<211>15
<212>PRT
＜213〉artificial sequence
<400>6
Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser
1 5 10 15
<210>7
<211>786
<212>DNA
＜213〉artificial sequence
<400>7
atgggattca?gcaggatctt?tctcttcctc?ctgtcagtaa?ctacaggtgt?ccactcccag 60
gtacaactac?agcagcctgg?ggctgagctg?gtgaagcctg?gggcctcagt?gaagatgtcc 120
tgcaaggctt?ctggctacac?atttaccagt?tacaatatgc?actgggtaaa?gcagacacct 180
ggtcggggcc?tggaatggat?tggagctatt?tatccaggaa?atggtgatac?ttcctacaat 240
cagaagttca?agggcaaggc?cacactgact?gcagacaaat?cctccagcac?agcctacatg 300
cagctcagca?gcctgacatc?tgaagactct?gcggtctatt?actgtgcaag?atcgacttac 360
tacggcggtg?actggtactt?caatgtctgg?ggcgcaggga?ccacggtcac?cgtctctgca 420
ggcggtggag?gctctggtgg?aggcggttca?ggaggcggtg?gatctcaaat?tgttctctcc 480
cagtctccag?caatcctgtc?tgcatctcca?ggggagaagg?tcacaatgac?ttgcagggcc 540
agctcaagtg?taagttacat?ccactggttc?cagcagaagc?caggatcctc?ccccaaaccc 600
tggatttatg?ccacatccaa?cctggcttct?ggagtccctg?ttcgcttcag?tggcagtggg 660
tctgggacct?cttactctct?cacaatcagt?agagtggagg?ctgaagatgc?tgccacttat 720
tactgccagc?agtggactag?taacccaccc?acgttcggtg?gtgggaccaa?gctggagatc 780
aaacga 786
<210>8
<211>262
<212>PRT
＜213〉artificial sequence
<400>8
Met?Gly?Phe?Ser?Arg?Ile?Phe?Leu?Phe?Leu?Leu?Ser?Val?Thr?Thr?Gly
1 5 10 15
Val?His?Ser?Gln?Val?Gln?Leu?Gln?Gln?Pro?Gly?Ala?Glu?Leu?Val?Lys
20 25 30
Pro?Gly?Ala?Ser?Val?Lys?Met?Ser?Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe
35 40 45
Thr?Ser?Tyr?Asn?Met?His?Trp?Val?Lys?Gln?Thr?Pro?Gly?Arg?Gly?Leu
50 55 60
Glu?Trp?Ile?Gly?Ala?Ile?Tyr?Pro?Gly?Asn?Gly?Asp?Thr?Ser?Tyr?Asn
65 70 75 80
Gln?Lys?Phe?Lys?Gly?Lys?Ala?Thr?Leu?Thr?Ala?Asp?Lys?Ser?Ser?Ser
85 90 95
Thr?Ala?Tyr?Met?Gln?Leu?Ser?Ser?Leu?Thr?Ser?Glu?Asp?Ser?Ala?Val
100 105 110
Tyr?Tyr?Cys?Ala?Arg?Ser?Thr?Tyr?Tyr?Gly?Gly?Asp?Trp?Tyr?Phe?Asn
115 120 125
Val?Trp?Gly?Ala?Gly?Thr?Thr?Val?Thr?Val?Ser?Ala?Gly?Gly?Gly?Gly
130 135 140
Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gln?Ile?Val?Leu?Ser
145 150 155 160
Gln?Ser?Pro?Ala?Ile?Leu?Ser?Ala?Ser?Pro?Gly?Glu?Lys?Val?Thr?Met
165 170 175
Thr?Cys?Arg?Ala?Ser?Ser?Ser?Val?Ser?Tyr?Ile?His?Trp?Phe?Gln?Gln
180 185 190
Lys?Pro?Gly?Ser?Ser?Pro?Lys?Pro?Trp?Ile?Tyr?Ala?Thr?Ser?Asn?Leu
195 200 205
Ala?Ser?Gly?Val?Pro?Val?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Ser
210 215 220
Tyr?Ser?Leu?Thr?Ile?Ser?Arg?Val?Glu?Ala?Glu?Asp?Ala?Ala?Thr?Tyr
225 230 235 240
Tyr?Cys?Gln?Gln?Trp?Thr?Ser?Asn?Pro?Pro?Thr?Phe?Gly?Gly?Gly?Thr
245 250 255
Lys?Leu?Glu?Ile?Lys?Arg
260
<210>9
<211>792
<212>DNA
＜213〉artificial sequence
<400>9
atggagttgg?gactgagctg?gattttcctt?ttggctattt?taaaaggtgt?ccagtgtgaa 60
gtgcagctgg?tggagtctgg?gggaggcttg?gtacagcctg?gcaggtccct?gagactctcc 120
tgtgcagcct?ctggattcac?ctttaatgat?tatgccatgc?actgggtccg?gcaagctcca 180
gggaagggcc?tggagtgggt?ctcaactatt?agttggaata?gtggttccat?aggctatgcg 240
gactctgtga?agggccgatt?caccatctcc?agagacaacg?ccaagaagtc?cctgtatctg 300
caaatgaaca?gtctgagagc?tgaggacacg?gccttgtatt?actgtgcaaa?agatatacag 360
tacggcaact?actactacgg?tatggacgtc?tggggccaag?ggaccacggt?caccgtctcc 420
tcaggtggtg?gaggctctgg?tggaggtggt?tcaggaggag?gtggatctga?aattgtgttg 480
acacagtctc?cagccacttt?atctttgtct?ccaggggaga?gagccaccct?ctcctgcagg 540
gccagtcaga?gtgttagcag?ctacttggca?tggtaccaac?agaaacctgg?ccaggctcct 600
aggctcctca?tctatgatgc?atccaacagg?gctacaggca?tcccagccag?gttcagtggc 660
agtgggtctg?ggacagactt?cactctcacc?atcagcagcc?tagagcctga?agattttgca 720
gtttattact?gtcagcagcg?tagcaactgg?ccgatcactt?tcggacaagg?gacccgactg 780
gagatcaaac?gt 792
<210>10
<211>264
<212>PRT
＜213〉artificial sequence
<400>10
Met?Glu?Leu?Gly?Leu?Ser?Trp?Ile?Phe?Leu?Leu?Ala?Ile?Leu?Lys?Gly
1 5 10 15
Val?Gln?Cys?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln
20 25 30
Pro?Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe
35 40 45
Asn?Asp?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu
50 55 60
Glu?Trp?Val?Ser?Thr?Ile?Ser?Trp?Asn?Ser?Gly?Ser?Ile?Gly?Tyr?Ala
65 70 75 80
Asp?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ala?Lys?Lys
85 90 95
Ser?Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Leu
100 105 110
Tyr?Tyr?Cys?Ala?Lys?Asp?Ile?Gln?Tyr?Gly?Asn?Tyr?Tyr?Tyr?Gly?Met
115 120 125
Asp?Val?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser?Gly?Gly?Gly
130 135 140
Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Glu?Ile?Val?Leu
145 150 155 160
Thr?Gln?Ser?Pro?Ala?Thr?Leu?Ser?Leu?Ser?Pro?Gly?Glu?Arg?Ala?Thr
165 170 175
Leu?Ser?Cys?Arg?Ala?Ser?Gln?Ser?Val?Ser?Ser?Tyr?Leu?Ala?Trp?Tyr
180 185 190
Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Arg?Leu?Leu?Ile?Tyr?Asp?Ala?Ser
195 200 205
Asn?Arg?Ala?Thr?Gly?Ile?Pro?Ala?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly
210 215 220
Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Glu?Pro?Glu?Asp?Phe?Ala
225 230 235 240
Val?Tyr?Tyr?Cys?Gln?Gln?Arg?Ser?Asn?Trp?Pro?Ile?Thr?Phe?Gly?Gln
245 250 255
Gly?Thr?Arg?Leu?Glu?Ile?Lys?Arg
260
<210>11
<211>915
<212>DNA
＜213〉artificial sequence
<400>11
gctagcacca?agggcccatc?ggtcttcccc?ctggcaccct?cctccaagag?cacctctggg 60
ggcacagcgg?ccctgggctg?cctggtcaag?gactacttcc?ccgaaccggt?gacggtgtct 120
tggaactcag?gcgccctgac?cagcggcgtg?cacaccttcc?cggctgtcct?acagtcctca 180
ggactctact?ccctcagcag?cgtggtgacc?gtgccctcca?gcagcttggg?cacccagacc 240
tacatctgca?acgtgaatca?caagcccagc?aacaccaagg?tggacaagaa?agttgagccc 300
aaatcttgtg?acaaaactca?cacatgccca?ccgtgcccag?cacctgaact?cctgggggga 360
ccgtcagtct?tcctcttccc?cccaaaaccc?aaggacaccc?tcatgatctc?ccggacccct 420
gaggtcacat?gcgtggtggt?ggacgtgagc?cacgaagacc?ctgaggtcaa?gttcaactgg 480
tacgtggacg?gcgtggagct?gcaccaggac?tggctgaatg?gcaaggagta?caagtgcaag 540
gtctccaaca?aagccctccc?agcccccatc?gagaaaacca?tctccaaagc?caaagggcag 600
ccccgagaac?cacaggtgta?caccctgccc?ccatcccggg?atgagctgac?caagaaccag 660
gtcagcctga?cctgcctggt?caaaggcttc?tatcccagcg?acatcgccgt?ggagtgggag 720
agcaatgggc?agccggagaa?caactacaag?accacgcctc?ccgtgctgga?ctccgacggc 780
tccttcttcc?tctacagcaa?gctcaccgtg?gacaagagca?ggtggcagca?ggggaacgtc 840
ttctcatgct?ccgtgatgca?tgaggctctg?cacaaccact?acacgcagaa?gagcctctcc 900
ctgtctcccg?gtaaa 915
<210>12
<211>305
<212>PRT
＜213〉artificial sequence
<400>12
Ala?Ser?Thr?Lys?Gly?Pro?Ser?Val?Phe?Pro?Leu?Ala?Pro?Ser?Ser?Lys
1 5 10 15
Ser?Thr?Ser?Gly?Gly?Thr?Ala?Ala?Leu?Gly?Cys?Leu?Val?Lys?Asp?Tyr
20 25 30
Phe?Pro?Glu?Pro?Val?Thr?Val?Ser?Trp?Asn?Ser?Gly?Ala?Leu?Thr?Ser
35 40 45
Gly?Val?His?Thr?Ph?Pro?Ala?Val?Leu?Gln?Asn?Val?Asn?His?Lys?Pro
50 55 60
Ser?Asn?Thr?Lys?Val?Asp?Lys?Lys?Val?Glu?Pro?Lys?Ser?Cys?Asp?Lys
65 70 75 80
Thr?His?Thr?Cys?Pro?Pro?Cys?Pro?Ala?Pro?Glu?Leu?Leu?Gly?Gly?Pro
85 90 95
Ser?Val?Phe?Leu?Phe?Pro?Pro?Lys?Pro?Lys?Asp?Thr?Leu?Met?Ile?Ser
100 105 110
Arg?Thr?Pro?Glu?Val?Thr?Cys?Val?Val?Val?Asp?Val?Ser?His?Glu?Asp
115 120 125
Pro?Glu?Val?Lys?Phe?Asn?Trp?Tyr?Val?Asp?Gly?Val?Glu?Val?His?Asn
130 135 140
Ala?Lys?Thr?Lys?Pro?Arg?Glu?Glu?Gln?Tyr?Asn?Ser?Thr?Tyr?Arg?Val
145 150 155 160
Val?Ser?Val?Leu?Thr?Val?Leu?His?Gln?Asp?Trp?Leu?Asn?Gly?Lys?Glu
165 170 175
Tyr?Lys?Cys?Lys?Val?Ser?Asn?Lys?Ala?Leu?Pro?Ala?Pro?Ile?Glu?Lys
180 185 190
Thr?Ile?Ser?Lys?Ala?Lys?Gly?Gln?Pro?Arg?Glu?Pro?Gln?Val?Tyr?Thr
195 200 205
Leu?Pro?Pro?Ser?Arg?Asp?Glu?Leu?Thr?Lys?Asn?Gln?Val?Ser?Leu?Thr
210 215 220
Cys?Leu?Val?Lys?Gly?Phe?Tyr?Pro?Ser?Asp?Ile?Ala?Val?Glu?Trp?Glu
225 230 235 240
Ser?Asn?Gly?Gln?Pro?Glu?Asn?Asn?Tyr?Lys?Thr?Thr?Pro?Pro?Val?Leu
245 250 255
Asp?Ser?Asp?Gly?Ser?Phe?Phe?Leu?Tyr?Ser?Lys?Leu?Thr?Val?Asp?Lys
260 265 270
Ser?Arg?Trp?Gln?Gln?Gly?Asn?Val?Phe?Ser?Cys?Ser?Val?Met?His?Glu
275 280 285
Ala?Leu?His?Asn?His?Tyr?Thr?Gln?Lys?Ser?Leu?Ser?Leu?Ser?Pro?Gly
290 295 300
Lys
305
<210>13
<211>711
<212>DNA
＜213〉artificial sequence
<400>13
gaattcgccg?ctgcagagcc?caaatctccc?gacaaaactc?acacatgccc?accgtgccca 60
gcacctgaac?tcctgggggg?accgtcagtc?ttcctcttcc?ccccaaaacc?caaggacacc 120
ctcatgatct?cccggacccc?tgaggtcaca?tgcgtggtgg?tggacgtgag?ccacgaagac 180
cctgaggtca?agttcaactg?gtacgtggac?ggcgtggagg?tgcataatgc?caagacaaag 240
ccgcgggagg?agcagtacaa?cagcacgtac?cgggtggtct?gcgtcctcac?cgtcctgcac 300
caggactggc?tgaatggcaa?ggagtacaag?tgcaaggtct?ccaacaaagc?cctcccagcc 360
cccatcgaga?aaaccatctc?caaagccaaa?gggcagcccc?gagaaccaca?ggtgtacacc 420
ctgcccccat?cccgggatga?gctgaccaag?aaccaggtca?gcctgacctg?cctggtcaaa 480
ggcttctatc?ccagcgacat?cgccgtggag?tgggagagca?atgggcagcc?ggagaacaac 540
tacaagacca?cgcctcccgt?gctggactcc?gacggctcct?tcttcctcta?cagcaagctc 600
accgtggaca?agagcaggtg?gcagcagggg?aacgtcttct?catgctccgt?gatgcatgag 660
gctctgcaca?accactacac?gcagaagagc?ctctccctgt?ctcccggtaa?a 711
<210>14
<211>237
<212>PRT
＜213〉artificial sequence
<400>14
Glu?Phe?Ala?Ala?Ala?Glu?Pro?Lys?Ser?Pro?Asp?Lys?Thr?His?Thr?Cys
1 5 10 15
Pro?Pro?Cys?Pro?Ala?Pro?Glu?Leu?Leu?Gly?Gly?Pro?Ser?Val?Phe?Leu
20 25 30
Phe?Pro?Pro?Lys?Pro?Lys?Asp?Thr?Leu?Met?Ile?Ser?Arg?Thr?Pro?Glu
35 40 45
Val?Thr?Cys?Val?Val?Val?Asp?Val?Ser?His?Glu?Asp?Pro?Glu?Val?Lys
50 55 60
Phe?Asn?Trp?Tyr?Val?Asp?Gly?Val?Glu?Val?His?Asn?Ala?Lys?Thr?Lys
65 70 75 80
Pro?Arg?Glu?Glu?Gln?Tyr?Asn?Ser?Thr?Tyr?Arg?Val?Val?Ser?Val?Leu
85 90 95
Thr?Val?Leu?His?Gln?Asp?Trp?Leu?Asn?Gly?Lys?Glu?Tyr?Lys?Cys?Lys
100 105 110
Val?Ser?Asn?Lys?Ala?Leu?Pro?Ala?Pro?Ile?Glu?Lys?Thr?Ile?Ser?Lys
115 120 125
Ala?Lys?Gly?Gln?Pro?Arg?Glu?Pro?Gln?Val?Tyr?Thr?Leu?Pro?Pro?Ser
130 135 140
Arg?Asp?Glu?Leu?Thr?Lys?Asn?Gln?Val?Ser?Leu?Thr?Cys?Leu?Val?Lys
145 150 155 160
Gly?Phe?Tyr?Pro?Ser?Asp?Ile?Ala?Val?Glu?Trp?Glu?Ser?Asn?Gly?Gln
165 170 175
Pro?Glu?Asn?Asn?Tyr?Lys?Thr?Thr?Pro?Pro?Val?Leu?Asp?Ser?Asp?Gly
180 185 190
Ser?Phe?Phe?Leu?Tyr?Ser?Lys?Leu?Thr?Val?Asp?Lys?Ser?Arg?Trp?Gln
195 200 205
Gln?Gly?Asn?Val?Phe?Ser?Cys?Ser?Val?Met?His?Glu?Ala?Leu?His?Asn
210 215 220
His?Tyr?Thr?Gln?Lys?Ser?Leu?Ser?Leu?Ser?Pro?Gly?Lys
225 230 235
<210>15
<211>15
<212>DNA
＜213〉artificial sequence
<400>15
gctagcactg?gtagt 15
<210>16
<211>5
<212>PRT
＜213〉artificial sequence
<400>16
Ala?Ser?Thr?Gly?Ser
1 5
<210>17
<211>2241
<212>DNA
＜213〉artificial sequence
<400>17
atgggattca?gcaggatctt?tctcttcctc?ctgtcagtaa?ctacaggtgt?ccactcccag 60
gtacaactac?agcagcctgg?ggctgagctg?gtgaagcctg?gggcctcagt?gaagatgtcc 120
tgcaaggctt?ctggctacac?atttaccagt?tacaatatgc?actgggtaaa?gcagacacct 180
ggtcggggcc?tggaatggat?tggagctatt?tatccaggaa?atggtgatac?ttcctacaat 240
cagaagttca?agggcaaggc?cacactgact?gcagacaaat?cctccagcac?agcctacatg 300
cagctcagca?gcctgacatc?tgaagactct?gcggtctatt?actgtgcaag?atcgacttac 360
tacggcggtg?actggtactt?caatgtctgg?ggcgcaggga?ccacggtcac?cgtctctgca 420
ggcggtggag?gctctggtgg?aggcggttca?ggaggcggtg?gatctcaaat?tgttctctcc 480
cagtctccag?caatcctgtc?tgcatctcca?ggggagaagg?tcacaatgac?ttgcagggcc 540
agctcaagtg?taagttacat?ccactggttc?cagcagaagc?caggatcctc?ccccaaaccc 600
tggatttatg?ccacatccaa?cctggcttct?ggagtccctg?ttcgcttcag?tggcagtggg 660
tctgggacct?cttactctct?cacaatcagt?agagtggagg?ctgaagatgc?tgccacttat 720
tactgccagc?agtggactag?taacccaccc?acgttcggtg?gtgggaccaa?gctggagatc 780
aaacgagcta?gcactggtag?tcaggtacaa?ctacagcagc?ctggggctga?gctggtgaag 840
cctggggcct?cagtgaagat?gtcctgcaag?gcttctggct?acacatttac?cagttacaat 900
atgcactggg?taaagcagac?acctggtcgg?ggcctggaat?ggattggagc?tatttatcca 960
ggaaatggtg?atacttccta?caatcagaag?ttcaagggca?aggccacact?gactgcagac 1020
aaatcctcca?gcacagccta?catgcagctc?agcagcctga?catctgaaga?ctctgcggtc 1080
tattactgtg?caagatcgac?ttactacggc?ggtgactggt?acttcaatgt?ctggggcgca 1140
gggaccacgg?tcaccgtctc?tgcaggcggt?ggaggctctg?gtggaggcgg?ttcaggaggc 1200
ggtggatctc?aaattgttct?ctcccagtct?ccagcaatcc?tgtctgcatc?tccaggggag 1260
aaggtcacaa?tgacttgcag?ggccagctca?agtgtaagtt?acatccactg?gttccagcag 1320
aagccaggat?cctcccccaa?accctggatt?tatgccacat?ccaacctggc?ttctggagtc 1380
cctgttcgct?tcagtggcag?tgggtctggg?acctcttact?ctctcacaat?cagtagagtg 1440
gaggctgaag?atgctgccac?ttattactgc?cagcagtgga?ctagtaaccc?acccacgttc 1500
ggtggtggga?ccaagctgga?gatcaaacga?gaattcgccg?ctgcagagcc?caaatctccc 1560
gacaaaactc?acacatgccc?accgtgccca?gcacctgaac?tcctgggggg?accgtcagtc 1620
ttcctcttcc?ccccaaaacc?caaggacacc?ctcatgatct?cccggacccc?tgaggtcaca 1680
tgcgtggtgg?tggacgtgag?ccacgaagac?cctgaggtca?agttcaactg?gtacgtggac 1740
ggcgtggagg?tgcataatgc?caagacaaag?ccgcgggagg?agcagtacaa?cagcacgtac 1800
cgggtggtct?gcgtcctcac?cgtcctgcac?caggactggc?tgaatggcaa?ggagtacaag 1860
tgcaaggtct?ccaacaaagc?cctcccagcc?cccatcgaga?aaaccatctc?caaagccaaa 1920
gggcagcccc?gagaaccaca?ggtgtacacc?ctgcccccat?cccgggatga?gctgaccaag 1980
aaccaggtca?gcctgacctg?cctggtcaaa?ggcttctatc?ccagcgacat?cgccgtggag 2040
tgggagagca?atgggcagcc?ggagaacaac?tacaagacca?cgcctcccgt?gctggactcc 2100
gacggctcct?tcttcctcta?cagcaagctc?accgtggaca?agagcaggtg?gcagcagggg 2160
aacgtcttct?catgctccgt?gatgcatgag?gctctgcaca?accactacac?gcagaagagc 2220
ctctccctgt?ctcccggtaa?a 2241
<210>18
<211>747
<212>PRT
＜213〉artificial sequence
<400>18
Met?Gly?Phe?Ser?Arg?Ile?Phe?Leu?Phe?Leu?Leu?Ser?Val?Thr?Thr?Gly
1 5 10 15
Val?His?Ser?Gln?Val?Gln?Leu?Gln?Gln?Pro?Gly?Ala?Glu?Leu?Val?Lys
20 25 30
Pro?Gly?Ala?Ser?Val?Lys?Met?Ser?Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe
35 40 45
Thr?Ser?Tyr?Asn?Met?His?Trp?Val?Lys?Gln?Thr?Pro?Gly?Arg?Gly?Leu
50 55 60
Glu?Trp?Ile?Gly?Ala?Ile?Tyr?Pro?Gly?Asn?Gly?Asp?Thr?Ser?Tyr?Asn
65 70 75 80
Gln?Lys?Phe?Lys?Gly?Lys?Ala?Thr?Leu?Thr?Ala?Asp?Lys?Ser?Ser?Ser
85 90 95
Thr?Ala?Tyr?Met?Gln?Leu?Ser?Ser?Leu?Thr?Ser?Glu?Asp?Ser?Ala?Val
100 105 110
Tyr?Tyr?Cys?Ala?Arg?Ser?Thr?Tyr?Tyr?Gly?Gly?Asp?Trp?Tyr?Phe?Asn
115 120 125
Val?Trp?Gly?Ala?Gly?Thr?Thr?Val?Thr?Val?Ser?Ala?Gly?Gly?Gly?Gly
130 135 140
Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gln?Ile?Val?Leu?Ser
145 150 155 160
Gln?Ser?Pro?Ala?Ile?Leu?Ser?Ala?Ser?Pro?Gly?Glu?Lys?Val?Thr?Met
165 170 175
Thr?Cys?Arg?Ala?Ser?Ser?Ser?Val?Ser?Tyr?Ile?His?Trp?Phe?Gln?Gln
180 185 190
Lys?Pro?Gly?Ser?Ser?Pro?Lys?Pro?Trp?Ile?Tyr?Ala?Thr?Ser?Asn?Leu
195 200 205
Ala?Ser?Gly?Val?Pro?Val?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Ser
210 215 220
Tyr?Ser?Leu?Thr?Ile?Ser?Arg?Val?Glu?Ala?Glu?Asp?Ala?Ala?Thr?Tyr
225 230 235 240
Tyr?Cys?Gln?Gln?Trp?Thr?Ser?Asn?Pro?Pro?Thr?Phe?Gly?Gly?Gly?Thr
245 250 255
Lys?Leu?Glu?Ile?Lys?Arg?Ala?Ser?Thr?Gly?Ser?Gln?Val?Gln?Leu?Gln
260 265 270
Gln?Pro?Gly?Ala?Glu?Leu?Val?Lys?Pro?Gly?Ala?Ser?Val?Lys?Met?Ser
275 280 285
Cys?Lys?Ala?Ser?Gly?Tyr?Thr?Phe?Thr?Ser?Tyr?Asn?Met?His?Trp?Val
290 295 300
Lys?Gln?Thr?Pro?Gly?Arg?Gly?Leu?Glu?Trp?Ile?Gly?Ala?Ile?Tyr?Pro
305 310 315 320
Gly?Asn?Gly?Asp?Thr?Ser?Tyr?Asn?Gln?Lys?Phe?Lys?Gly?Lys?Ala?Thr
325 330 335
Leu?Thr?Ala?Asp?Lys?Ser?Ser?Ser?Thr?Ala?Tyr?Met?Gln?Leu?Ser?Ser
340 345 350
Leu?Thr?Ser?Glu?Asp?Ser?Ala?Val?Tyr?Tyr?Cys?Ala?Arg?Ser?Thr?Tyr
355 360 365
Tyr?Gly?Gly?Asp?Trp?Tyr?Phe?Asn?Val?Trp?Gly?Ala?Gly?Thr?Thr?Val
370 375 380
Thr?Val?Ser?Ala?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly
385 390 395 400
Gly?Gly?Ser?Gln?Ile?Val?Leu?Ser?Gln?Ser?Pro?Ala?Ile?Leu?Ser?Ala
405 410 415
Ser?Pro?Gly?Glu?Lys?Val?Thr?Met?Thr?Cys?Arg?Ala?Ser?Ser?Ser?Val
420 425 430
Ser?Tyr?Ile?His?Trp?Phe?Gln?Gln?Lys?Pro?Gly?Ser?Ser?Pro?Lys?Pro
435 440 445
Trp?Ile?Tyr?Ala?Thr?Ser?Asn?Leu?Ala?Ser?Gly?Val?Pro?Val?Arg?Phe
450 455 460
Ser?Gly?Ser?Gly?Ser?Gly?Thr?Ser?Tyr?Ser?Leu?Thr?Ile?Ser?Arg?Val
465 470 475 480
Glu?Ala?Glu?Asp?Ala?Ala?Thr?Tyr?Tyr?Cys?Gln?Gln?Trp?Thr?Ser?Asn
485 490 495
Pro?Pro?Thr?Phe?Gly?Gly?Gly?Thr?Lys?Leu?Glu?Ile?Lys?Arg?Glu?Phe
500 505 510
Ala?Ala?Ala?Glu?Pro?Lys?Ser?Pro?Asp?Lys?Thr?His?Thr?Cys?Pro?Pro
515 520 525
Cys?Pro?Ala?Pro?Glu?Leu?Leu?Gly?Gly?Pro?Ser?Val?Phe?Leu?Phe?Pro
530 535 540
Pro?Lys?Pro?Lys?Asp?Thr?Leu?Met?Ile?Ser?Arg?Thr?Pro?Glu?Val?Thr
545 550 555 560
Cys?Val?Val?Val?Asp?Val?Ser?His?Glu?Asp?Pro?Glu?Val?Lys?Phe?Asn
565 570 575
Trp?Tyr?Val?Asp?Gly?Val?Glu?Val?His?Asn?Ala?Lys?Thr?Lys?Pro?Arg
580 585 590
Glu?Glu?Gln?Tyr?Asn?Ser?Thr?Tyr?Arg?Val?Val?Ser?Val?Leu?Thr?Val
595 600 605
Leu?His?Gln?Asp?Trp?Leu?Asn?Gly?Lys?Glu?Tyr?Lys?Cys?Lys?Val?Ser
610 615 620
Asn?Lys?Ala?Leu?Pro?Ala?Pro?Ile?Glu?Lys?Thr?Ile?Ser?Lys?Ala?Lys
625 630 635 640
Gly?Gln?Pro?Arg?Glu?Pro?Gln?Val?Tyr?Thr?Leu?Pro?Pro?Ser?Arg?Asp
645 650 655
Glu?Leu?Thr?Lys?Asn?Gln?Val?Ser?Leu?Thr?Cys?Leu?Val?Lys?Gly?Phe
660 665 670
Tyr?Pro?Ser?Asp?Ile?Ala?Val?Glu?Trp?Glu?Ser?Asn?Gly?Gln?Pro?Glu
675 680 685
Asn?Asn?Tyr?Lys?Thr?Thr?Pro?Pro?Val?Leu?Asp?Ser?Asp?Gly?Ser?Phe
690 695 700
Phe?Leu?Tyr?Ser?Lys?Leu?Thr?Val?Asp?Lys?Ser?Arg?Trp?Gln?Gln?Gly
705 710 715 720
Asn?Val?Phe?Ser?Cys?Ser?Val?Met?His?Glu?Ala?Leu?His?Asn?His?Tyr
725 730 735
Thr?Gln?Lys?Ser?Leu?Ser?Leu?Ser?Pro?Gly?Lys
740 745
<210>19
<211>2253
<212>DNA
＜213〉artificial sequence
<400>19
atggagttgg?gactgagctg?gattttcctt?ttggctattt?taaaaggtgt?ccagtgtgaa 60
gtgcagctgg?tggagtctgg?gggaggcttg?gtacagcctg?gcaggtccct?gagactctcc 120
tgtgcagcct?ctggattcac?ctttaatgat?tatgccatgc?actgggtccg?gcaagctcca 180
gggaagggcc?tggagtgggt?ctcaactatt?agttggaata?gtggttccat?aggctatgcg 240
gactctgtga?agggccgatt?caccatctcc?agagacaacg?ccaagaagtc?cctgtatctg 300
caaatgaaca?gtctgagagc?tgaggacacg?gccttgtatt?actgtgcaaa?agatatacag 360
tacggcaact?actactacgg?tatggacgtc?tggggccaag?ggaccacggt?caccgtctcc 420
tcaggtggtg?gaggctctgg?tggaggtggt?tcaggaggag?gtggatctga?aattgtgttg 480
acacagtctc?cagccacttt?atctttgtct?ccaggggaga?gagccaccct?ctcctgcagg 540
gccagtcaga?gtgttagcag?ctacttggca?tggtaccaac?agaaacctgg?ccaggctcct 600
aggctcctca?tctatgatgc?atccaacagg?gctacaggca?tcccagccag?gttcagtggc 660
agtgggtctg?ggacagactt?cactctcacc?atcagcagcc?tagagcctga?agattttgca 720
gtttattact?gtcagcagcg?tagcaactgg?ccgatcactt?tcggacaagg?gacccgactg 780
gagatcaaac?gtgctagcac?tggtagtgaa?gtgcagctgg?tggagtctgg?gggaggcttg 840
gtacagcctg?gcaggtccct?gagactctcc?tgtgcagcct?ctggattcac?ctttaatgat 900
tatgccatgc?actgggtccg?gcaagctcca?gggaagggcc?tggagtgggt?ctcaactatt 960
agttggaata?gtggttccat?aggctatgcg?gactctgtga?agggccgatt?caccatctcc 1020
agagacaacg?ccaagaagtc?cctgtatctg?caaatgaaca?gtctgagagc?tgaggacacg 1080
gccttgtatt?actgtgcaaa?agatatacag?tacggcaact?actactacgg?tatggacgtc 1140
tggggccaag?ggaccacggt?caccgtctcc?tcaggtggtg?gaggctctgg?tggaggtggt 1200
tcaggaggag?gtggatctga?aattgtgttg?acacagtctc?cagccacttt?atctttgtct 1260
ccaggggaga?gagccaccct?ctcctgcagg?gccagtcaga?gtgttagcag?ctacttggca 1320
tggtaccaac?agaaacctgg?ccaggctcct?aggctcctca?tctatgatgc?atccaacagg 1380
gctacaggca?tcccagccag?gttcagtggc?agtgggtctg?ggacagactt?cactctcacc 1440
atcagcagcc?tagagcctga?agattttgca?gtttattact?gtcagcagcg?tagcaactgg 1500
ccgatcactt?tcggacaagg?gacccgactg?gagatcaaac?gtgaattcgc?cgctgcagag 1560
cccaaatctc?ctgacaaaac?tcacacatgc?ccaccgtgcc?cagcacctga?actcctgggg 1620
ggaccgtcag?tcttcctctt?ccccccaaaa?cccaaggaca?ccctcatgat?ctcccggacc 1680
cctgaggtca?catgcgtggt?ggtggacgtg?agccacgaag?accctgaggt?caagttcaac 1740
tggtacgtgg?acggcgtgga?ggtgcataat?gccaagacaa?agccgcggga?ggagcagtac 1800
aacagcacgt?accgtgtggt?cagcgtcctc?accgtcctgc?accaggactg?gctgaatggc 1860
aaggagtaca?agtgcaaggt?ctccaacaaa?gccctcccag?cccccatcga?gaaaaccatc 1920
tccaaagcca?aagggcagcc?ccgagaacca?caggtgtaca?ccctgccccc?atcccgggat 1980
gagctgacca?agaaccaggt?cagcctgacc?tgcctggtca?aaggcttcta?tcccagcgac 2040
atcgccgtgg?agtgggagag?caatgggcag?ccggagaaca?actacaagac?cacgcctccc 2100
gtgctggact?ccgacggctc?cttcttcctc?tacagcaagc?tcaccgtgga?caagagcagg 2160
tggcagcagg?ggaacgtctt?ctcatgctcc?gtgatgcatg?aggctctgca?caaccactac 2220
acgcagaaga?gcctctccct?gtctcccggt?aaa 2253
<210>20
<211>751
<212>PRT
＜213〉artificial sequence
<400>20
Met?Glu?Leu?Gly?Leu?Ser?Trp?Ile?Phe?Leu?Leu?Ala?Ile?Leu?Lys?Gly
1 5 10 15
Val?Gln?Cys?Glu?Val?Gln?Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln
20 25 30
Pro?Gly?Arg?Ser?Leu?Arg?Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe
35 40 45
Asn?Asp?Tyr?Ala?Met?His?Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu
50 55 60
Glu?Trp?Val?Ser?Thr?Ile?Ser?Trp?Asn?Ser?Gly?Ser?Ile?Gly?Tyr?Ala
65 70 75 80
Asp?Ser?Val?Lys?Gly?Arg?Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ala?Lys?Lys
85 90 95
Ser?Leu?Tyr?Leu?Gln?Met?Asn?Ser?Leu?Ara?Ala?Glu?Asp?Thr?Ala?Leu
100 105 110
Tyr?Tyr?Cys?Ala?Lys?Asp?Ile?Gln?Tyr?Gly?Asn?Tyr?Tyr?Tyr?Gly?Met
115 120 125
Asp?Val?Trp?Gly?Gln?Gly?Thr?Thr?Val?Thr?Val?Ser?Ser?Gly?Gly?Gly
130 135 140
Gly?Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly?Ser?Glu?Ile?Val?Leu
145 150 155 160
Thr?Gln?Ser?Pro?Ala?Thr?Leu?Ser?Leu?Ser?Pro?Gly?Glu?Arg?Ala?Thr
165 170 175
Leu?Ser?Cys?Arg?Ala?Ser?Gln?Ser?Val?Ser?Ser?Tyr?Leu?Ala?Trp?Tyr
180 185 190
Gln?Gln?Lys?Pro?Gly?Gln?Ala?Pro?Arg?Leu?Leu?Ile?Tyr?Asp?Ala?Ser
195 200 205
Asn?Arg?Ala?Thr?Gly?Ile?Pro?Ala?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly
210 215 220
Thr?Asp?Phe?Thr?Leu?Thr?Ile?Ser?Ser?Leu?Glu?Pro?Glu?Asp?Phe?Ala
225 230 235 240
Val?Tyr?Tyr?Cys?Gln?Gln?Arg?Ser?Asn?Trp?Pro?Ile?Thr?Phe?Gly?Gln
245 250 255
Gly?Thr?Arg?Leu?Glu?Ile?Lys?Arg?Ala?Ser?Thr?Gly?Ser?Glu?Val?Gln
260 265 270
Leu?Val?Glu?Ser?Gly?Gly?Gly?Leu?Val?Gln?Pro?Gly?Arg?Ser?Leu?Arg
275 280 285
Leu?Ser?Cys?Ala?Ala?Ser?Gly?Phe?Thr?Phe?Asn?Asp?Tyr?Ala?Met?His
290 295 300
Trp?Val?Arg?Gln?Ala?Pro?Gly?Lys?Gly?Leu?Glu?Trp?Val?Ser?Thr?Ile
305 310 315 320
Ser?Trp?Asn?Ser?Gly?Ser?Ile?Gly?Tyr?Ala?Asp?Ser?Val?Lys?Gly?Arg
325 330 335
Phe?Thr?Ile?Ser?Arg?Asp?Asn?Ala?Lys?Lys?Ser?Leu?Tyr?Leu?Gln?Met
340 345 350
Asn?Ser?Leu?Arg?Ala?Glu?Asp?Thr?Ala?Leu?Tyr?Tyr?Cys?Ala?Lys?Asp
355 360 365
Ile?Gln?Tyr?Gly?Asn?Tyr?Tyr?Tyr?Gly?Met?Asp?Val?Trp?Gly?Gln?Gly
370 375 380
Thr?Thr?Val?Thr?Val?Ser?Ser?Gly?Gly?Gly?Gly?Ser?Gly?Gly?Gly?Gly
385 390 395 400
Ser?Gly?Gly?Gly?Gly?Ser?Glu?Ile?Val?Leu?Thr?Gln?Ser?Pro?Ala?Thr
405 410 415
Leu?Ser?Leu?Ser?Pro?Gly?Glu?Arg?Ala?Thr?Leu?Ser?Cys?Arg?Ala?Ser
420 425 430
Gln?Ser?Val?Ser?Ser?Tyr?Leu?Ala?Trp?Tyr?Gln?Gln?Lys?Pro?Gly?Gln
435 440 445
Ala?Pro?Arg?Leu?Leu?Ile?Tyr?Asp?Ala?Ser?Asn?Arg?Ala?Thr?Gly?Ile
450 455 460
Pro?Ala?Arg?Phe?Ser?Gly?Ser?Gly?Ser?Gly?Thr?Asp?Phe?Thr?Leu?Thr
465 470 475 480
Ile?Ser?Ser?Leu?Glu?Pro?Glu?Asp?Phe?Ala?Val?Tyr?Tyr?Cys?Gln?Gln
485 490 495
Arg?Ser?Asn?Trp?Pro?Ile?Thr?Phe?Gly?Gln?Gly?Thr?Arg?Leu?Glu?Ile
500 505 510
Lys?Arg?Glu?Phe?Ala?Ala?Ala?Glu?Pro?Lys?Ser?Cys?Asp?Lys?Thr?His
515 520 525
Thr?Cys?Pro?Pro?Cys?Pro?Ala?Pro?Glu?Leu?Leu?Gly?Gly?Pro?Ser?Val
530 535 540
Phe?Leu?Phe?Pro?Pro?Lys?Pro?Lys?Asp?Thr?Leu?Met?Ile?Ser?Arg?Thr
545 550 555 560
Pro?Glu?ValThr?Cys?Val?Val?Val?Asp?Val?Ser?His?Glu?Asp?Pro?Glu
565 570 575
Val?Lys?Phe?Asn?Trp?Tyr?Val?Asp?Gly?Val?Glu?Val?His?Asn?Ala?Lys
580 585 590
Thr?Lys?Pro?Arg?Glu?Glu?Gln?Tyr?Asn?Ser?Thr?Tyr?Arg?Val?Val?Ser
595 600 605
Val?Leu?Thr?Val?Leu?His?Gln?Asp?Trp?Leu?Asn?Gly?Lys?Glu?Tyr?Lys
610 615 620
Cys?Lys?Val?Ser?Asn?Lys?Ala?Leu?Pro?Ala?Pro?Ile?Glu?Lys?Thr?Ile
625 630 635 640
Ser?Lys?Lya?Lys?Gly?Gln?Pro?Arg?Glu?Pro?Gln?Val?Tyr?Thr?Leu?Pro
645 650 655
Pro?Ser?Arg?Asp?Glu?Leu?Thr?Lys?Asn?Gln?Val?Ser?Leu?Thr?Cys?Leu
660 665 670
Val?Lys?Gly?Phe?Tyr?Pro?Ser?Asp?Ile?Ala?Val?Glu?Trp?Glu?Ser?Asn
675 680 685
Gly?Gln?Pro?Glu?Asn?Asn?Tyr?Lys?Thr?Thr?Pro?Pro?Val?Leu?Asp?Ser
690 695 700
Asp?Gly?Ser?Phe?Phe?Leu?Tyr?Ser?Lys?Leu?Thr?Val?Asp?Lys?Ser?Arg
705 710 715 720
Trp?Gln?Gln?Gly?Asn?Val?Phe?Ser?Cys?Ser?Val?Met?His?Glu?Ala?Leu
725 730 735
His?Asn?His?Tyr?Thr?Gln?Lys?Ser?Leu?Ser?Leu?Ser?Pro?Gly?Lys
740 745 750
Claims (13)
1. anti-CD 20 tetravalent antibody.
2. the described anti-CD 20 tetravalent antibody of claim 1 is C2B8 (ScFvHL)
4-Fc.
3. the described anti-CD 20 tetravalent antibody of claim 2, its aminoacid sequence is SEQ ID NO:18.
4. the nucleotide sequence of the described anti-CD 20 tetravalent antibody of coding claim 3 is SEQ ID NO:17.
5. the described anti-CD 20 tetravalent antibody of claim 1 is 2F2 (ScFvHL)
4-Fc.
6. the described anti-CD 20 tetravalent antibody of claim 5, its aminoacid sequence is SEQ ID NO:20.
7. the nucleotide sequence of the described anti-CD 20 tetravalent antibody of coding claim 6 is SEQ ID NO:19.
8. prepare the method for claim 1,2,3,5,6 arbitrary described anti-CD 20 tetravalent antibodies, comprising:
A. the single-chain antibody ScFv and the clone that make up CD20 monoclonal antibody C2B8 or 2F2 obtain people's IgG antibody 1Fc gene;
B. link to each other with people's antibody Fc section gene again after 2 identical single-chain antibody genes being connected in series and obtain fusion gene;
C. the fusion gene cloning that step b is obtained is built into carrier for expression of eukaryon pcDNA3.1 (C2B8 (ScFvHL) to carrier for expression of eukaryon pcDNA3.1 (+)
2Fc) or pcDNA3.1 (2F2 (ScFvHL)
2Fc);
D. the expression vector pcDNA3.1 that step c is obtained (C2B8 (ScFvHL)
2Fc) or pcDNA3.1 (2F2 (ScFvHL)
2Fc) transfection CHO cell, subclone is carried out in screening, and with the high-expression clone enlarged culturing that screening obtains, separation and purification is promptly.
9. a preparation contains above-mentioned 1,2,3,5,6 arbitrary described antibody and pharmaceutically useful carriers.
Claim 1,2,3,5,6,9 arbitrary described antibody or preparation the preparation anti-B cell lymphoma medicine in purposes.
11. the purposes of claim 10, wherein B cell lymphoma is a non-Hodgkin lymphoma.
12. the purposes of claim 11, wherein non-Hodgkin lymphoma is low and part moderate non-Hodgkin lymphoma.
13. the purposes of claim 10, wherein B cell lymphoma is a chronic lymphatic leukemia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA2007101938601A CN101205255A (en) | 2006-12-14 | 2007-12-03 | Anti CD20 tetravalent antibody, preparation method and uses thereof |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610147283 | 2006-12-14 | ||
| CN200610147283.8 | 2006-12-14 | ||
| CNA2007101938601A CN101205255A (en) | 2006-12-14 | 2007-12-03 | Anti CD20 tetravalent antibody, preparation method and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101205255A true CN101205255A (en) | 2008-06-25 |
Family
ID=39565752
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA2007101938601A Pending CN101205255A (en) | 2006-12-14 | 2007-12-03 | Anti CD20 tetravalent antibody, preparation method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101205255A (en) |
Cited By (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102030826A (en) * | 2009-09-25 | 2011-04-27 | 上海抗体药物国家工程研究中心有限公司 | High-affinity CD20-resistance monoclonal antibody |
| CN102448985A (en) * | 2009-05-27 | 2012-05-09 | 霍夫曼-拉罗奇有限公司 | Tri- or tetraspecific antibodies |
| CN102050879B (en) * | 2009-10-30 | 2014-02-19 | 上海抗体药物国家工程研究中心有限公司 | Anti-human CD20 humanized antibody and preparation method and application thereof |
| CN102050878B (en) * | 2009-10-30 | 2014-04-02 | 上海抗体药物国家工程研究中心有限公司 | Anti-human CD20 humanized antibody and preparation method and application thereof |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| CN105779490A (en) * | 2014-12-16 | 2016-07-20 | 北京集智新创科技有限公司 | Construction method of Pichia pastoris expressed by OCH1 defect anti-CD20 tetravalent antibody |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
| US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
| US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
| US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US10138293B2 (en) | 2007-12-21 | 2018-11-27 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
| US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
| US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
-
2007
- 2007-12-03 CN CNA2007101938601A patent/CN101205255A/en active Pending
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10927163B2 (en) | 2007-12-21 | 2021-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US10138293B2 (en) | 2007-12-21 | 2018-11-27 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US9382323B2 (en) | 2009-04-02 | 2016-07-05 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
| US9890204B2 (en) | 2009-04-07 | 2018-02-13 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| US11993642B2 (en) | 2009-04-07 | 2024-05-28 | Hoffmann-La Roche Inc. | Trivalent, bispecific antibodies |
| CN102448985A (en) * | 2009-05-27 | 2012-05-09 | 霍夫曼-拉罗奇有限公司 | Tri- or tetraspecific antibodies |
| US8796424B2 (en) | 2009-05-27 | 2014-08-05 | Hoffmann-La Roche Inc. | Tri- or tetraspecific antibodies |
| CN102448985B (en) * | 2009-05-27 | 2015-08-05 | 霍夫曼-拉罗奇有限公司 | Three or four specific antibodies |
| US10640555B2 (en) | 2009-06-16 | 2020-05-05 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| US11673945B2 (en) | 2009-06-16 | 2023-06-13 | Hoffmann-La Roche Inc. | Bispecific antigen binding proteins |
| US9994646B2 (en) | 2009-09-16 | 2018-06-12 | Genentech, Inc. | Coiled coil and/or tether containing protein complexes and uses thereof |
| CN102030826A (en) * | 2009-09-25 | 2011-04-27 | 上海抗体药物国家工程研究中心有限公司 | High-affinity CD20-resistance monoclonal antibody |
| CN102030826B (en) * | 2009-09-25 | 2014-10-29 | 上海抗体药物国家工程研究中心有限公司 | High-affinity CD20-resistance monoclonal antibody |
| CN102050878B (en) * | 2009-10-30 | 2014-04-02 | 上海抗体药物国家工程研究中心有限公司 | Anti-human CD20 humanized antibody and preparation method and application thereof |
| CN102050879B (en) * | 2009-10-30 | 2014-02-19 | 上海抗体药物国家工程研究中心有限公司 | Anti-human CD20 humanized antibody and preparation method and application thereof |
| US10106600B2 (en) | 2010-03-26 | 2018-10-23 | Roche Glycart Ag | Bispecific antibodies |
| US9879095B2 (en) | 2010-08-24 | 2018-01-30 | Hoffman-La Roche Inc. | Bispecific antibodies comprising a disulfide stabilized-Fv fragment |
| US11618790B2 (en) | 2010-12-23 | 2023-04-04 | Hoffmann-La Roche Inc. | Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery |
| US9982036B2 (en) | 2011-02-28 | 2018-05-29 | Hoffmann-La Roche Inc. | Dual FC antigen binding proteins |
| US10611825B2 (en) | 2011-02-28 | 2020-04-07 | Hoffmann La-Roche Inc. | Monovalent antigen binding proteins |
| US10793621B2 (en) | 2011-02-28 | 2020-10-06 | Hoffmann-La Roche Inc. | Nucleic acid encoding dual Fc antigen binding proteins |
| US9688758B2 (en) | 2012-02-10 | 2017-06-27 | Genentech, Inc. | Single-chain antibodies and other heteromultimers |
| US11407836B2 (en) | 2012-06-27 | 2022-08-09 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US11421022B2 (en) | 2012-06-27 | 2022-08-23 | Hoffmann-La Roche Inc. | Method for making antibody Fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof |
| US10106612B2 (en) | 2012-06-27 | 2018-10-23 | Hoffmann-La Roche Inc. | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| US10323099B2 (en) | 2013-10-11 | 2019-06-18 | Hoffmann-La Roche Inc. | Multispecific domain exchanged common variable light chain antibodies |
| US10633457B2 (en) | 2014-12-03 | 2020-04-28 | Hoffmann-La Roche Inc. | Multispecific antibodies |
| US11999801B2 (en) | 2014-12-03 | 2024-06-04 | Hoffman-La Roche Inc. | Multispecific antibodies |
| CN105779490A (en) * | 2014-12-16 | 2016-07-20 | 北京集智新创科技有限公司 | Construction method of Pichia pastoris expressed by OCH1 defect anti-CD20 tetravalent antibody |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101205255A (en) | Anti CD20 tetravalent antibody, preparation method and uses thereof | |
| AU2025202863A1 (en) | Anti-CDH6 antibody and anti-CDH6 antibody-drug conjugate | |
| KR101972446B1 (en) | Bcma(cd269/tnfrsf17)-binding proteins | |
| EP2992013B1 (en) | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b | |
| KR102763369B1 (en) | Multi-specific antibodies and methods for producing them and uses thereof | |
| CN113939536B (en) | TIGIT and PD-1/TIGIT-binding molecules | |
| KR20060126659A (en) | Chimeric Anti-CD44 Antibody and its Acute Myeloid Leukemia Treatment | |
| KR20150139909A (en) | Bispecific antibodies specific for fap and dr5, antibodies specific for dr5 and methods of use | |
| KR20180105736A (en) | TCR Complex immunotherapeutics | |
| KR20240019218A (en) | T cell engager molecules and uses thereof | |
| KR20160045134A (en) | Bi-specific monovalent diabodies that are capable of binding cd123 and cd3, and uses therof | |
| KR20100021601A (en) | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto | |
| CN114634570A (en) | Antigen binding molecules comprising TNF family ligand trimers | |
| KR20110004455A (en) | Anti-FLT3 antibodies | |
| CN108659112B (en) | Asymmetric bispecific antibody | |
| AU2018307292B2 (en) | Anti-CD147 antibody | |
| CN107949575B (en) | CYS80 conjugated immunoglobulin | |
| CN109536476A (en) | Targent fused protein, the Preparation method and use for having hyaluronidase activity | |
| CN104558194B (en) | A kind of anti-CD20-Flex bifunctional fusion proteins, preparation method and the usage | |
| KR20110084996A (en) | Anti-ferroportin 1 monoclonal antibody and uses thereof | |
| CN107759691A (en) | A kind of specific binding AXL monoclonal antibody | |
| CN104610453A (en) | Anti-HER2 dual-targeting antibodies, and preparation method and application thereof | |
| KR20240017054A (en) | Treatment of PD-L1 negative or low-expressing cancers using anti-ICOS antibodies | |
| CN104447993A (en) | Human anti-HER2 monoclonal antibody with high activity, and preparation method and application thereof | |
| CN114515335A (en) | Use of anti-OX 40 antibodies in the treatment of tumors or cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Free format text: FORMER OWNER: SHANGHAI GUOJIAN BIOTECHNOLOGY INSTITUTE Owner name: ANTIBODIES NATIONAL ENGINEERING RESEARCH CENTER Free format text: FORMER OWNER: SHANGHAI CP GUOJIAN PHARMACEUTICAL CO., LTD. Effective date: 20110330 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG NEW DISTRICT, SHANGHAI TO: 201203 BUILDING 3, NO. 399, LIBING ROAD, ZHANGJIANG HIGH-TECH. PARK, PUDONG NEW DISTRICT, SHANGHAI |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20110330 Address after: Shanghai city 201203 libing road Zhangjiang High Tech Park of Pudong New Area No. 399 building 3 Applicant after: Antibodies National Engineering Research Center Address before: Shanghai city 201203 libing road Pudong New Area Zhangjiang hi tech Park No. 399 Applicant before: Shanghai CP Guojian Pharmaceutical Co., Ltd. Co-applicant before: Shanghai Guojian Biological Technology Institute |
|
| AD01 | Patent right deemed abandoned |
Effective date of abandoning: 20080625 |
|
| C20 | Patent right or utility model deemed to be abandoned or is abandoned |